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ABSTRACT 
Oral mucositis [OM] is one of the most severe non-hematological problems related to 
cancer treatments and can impact quality of life.  It is linked to poorer outcomes due to the 
associated weight loss, pain, dehydration, and risk of developing life-threatening infections.  The 
purpose of this evidence-based practice project was to determine if OM is preventable with the 
use of an oral care protocol and zinc supplementation when compared to use of oral care 
protocols alone.  The Johns Hopkins Nursing Evidence-Based Practice Model was used to 
guide project implementation in an outpatient oncology office.  Recommendations were 
developed from an exhaustive review of literature.  Implementation of the project occurred in 
two phases.  Phase one was establishment and implementation of an oral care protocol as the 
standard of care.  Phase two included the standard of care and incorporated use of zinc 
supplements to select participants. Groups were selected by convenience sampling. A two-
group pretest-posttest quasi-experimental design was applied.  OM Symptoms were tracked 
using the Patient Reported Oral Mucositis Symptom (PROMS) survey, a visual analog scale 
consisting of ten questions.  Participants (N=23) filled out baseline surveys and were followed 
over a six-week period.  Independent t-test were used to analyze the data. Statistically 
significant results were noted in 8 out of 10 variables assessed using PROMS: Mouth pain, 
weeks 5 (2.91 vs. 8.75, p = .046) and 6 (2 vs. 8.91, p = .004), difficulty speaking, weeks 4 (2.7 
vs. 7.33, p = .008) and 6 (1.18 vs. 3.36, p = .036), eating soft foods, weeks 3 (2 vs. 4.2, p = 
.024) and 5 (1.82 vs. 7.25, p = .008), restriction of eating week 6 (3.45 vs. 11.82, p = .017), 
difficulty drinking weeks 5 (2 vs. 5, p = .024) and 6 (1.36 vs. 3.73, p = .023, restriction of drinking 
week 3 (1.2 vs. 2.7, p = .033), difficulty swallowing weeks 4 (2 vs. 6.89, p = .048) and 5 (1.91 vs. 
8.25, p = .027), and change in weeks 4 (6.3 vs. 14.33, p = .045) and 5 (4.55 vs. 16.88, p = 
.04)(Figure 4.8). There were no statistically significant differences in the groups with regards to 
restriction of speech or difficulty eating hard foods. 
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CHAPTER 1 
INTRODUCTION 
Background 
 Cancer is the collective name given to malignant processes that can start anywhere in 
the human body, occurring when some of the body’s cells begin to divide without physical 
restrictions and can spread into other tissues (National Cancer Institute [NCI], 2015).  Cancer 
can occur at any time during the lifespan.  The second leading cause of death worldwide is 
cancer (WHO, 2018).  In the United States, it is estimated that 38.4% of men and women will be 
diagnosed with cancer during their lifetime (NCI, 2018).  Five-year survival rates for 2016 are 
67% after treatment, however, data does not provide type of treatments given, nor distinguish 
route oncological methods are delivered (Miller et al., 2016).  There are several methods of 
oncological treatment, such as chemotherapy, radiation treatment, surgery, hormonal therapy, 
and immune therapy (American Cancer Society [ACS], 2016).  This paper addresses 
chemotherapy and radiation treatments as they are most commonly linked with oral mucositis 
(OM) with prevalence rates from 20-100% depending on cancer type and stage, characteristics 
of a tumor, the patient’s age, and overall health status (ACS, 2016, Cidon, 2018 & Slade, 2017). 
For many cancers, there are oncological treatments that can alleviate or cure specific 
cancer types.  The cytotoxic effects of oncological therapies can disrupt normal tissues, 
especially those of the oral mucosa (Cullen et al., 2018).  Oral mucositis is a complicated 
process of ulceration that involves many different factors and is considered one of the most 
severe non-hematological complications leading to pain, decreased quality of life, and life-
threatening infections (Campos, Campos, Aarestrup, & Aarestrup, 2014 & Eilers, Harris, Henry 
& Johnson, 2014 & Slade, 2017).  Preventing OM helps reduce the risk for several 
complications from oncological therapies, including oral infections, malnutrition, and dehydration 
in individuals.  Discomfort is one common symptom that patients experience with OM: However, 
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clinical tools do not always capture the subjective experience.  Inconsistency exists in the 
evaluation of OM and can vary significantly across tools, objective assessments, and 
documentation.  
Pathophysiology of Oral Mucositis 
Once thought to be a simple pathway that was unavoidable during oncological 
treatments, OM is now understood as a complex pathophysiological process (Eilers et al., 2014; 
Campos et al., 2014).  This condition mostly affects nonkeratinized mucosa, particularly the 
buccal mucosa, soft palate, floor of the mouth, lateral edges of the tongue and lips (Carvalho, 
Medeiros-Filho, & Ferreira, 2018).  This condition typically occurs in four stages: the initial 
stage, epithelia stage, ulceration stage, and healing stage.  
The initial stage is triggered when the initial stimulus of the oncological treatment is 
introduced and causes a reactive oxygen species reaction within the oral mucosa (Campos et 
al., 2014; Panahi, Saadat, Shadboorestan & Ahmadi, 2016).  A reactive oxygen species is an 
unstable molecule that easily interacts with other parts of the cell, and when there is a buildup of 
these molecules, they may cause damage to DNA, RNA, proteins, and cause cell death 
(Görlach et al, 2015).   
In the epithelia stage, apoptosis has occurred in most of the epithelial cells lining the oral 
cavity. Furthermore, surviving cells are unable to be replicate due to errors in protein synthesis, 
leading to widespread denudation, inflammation, and ulceration (Campos et al., 2014; Eilers et 
al., 2016 & Panahi et al., 2016).   
The next stage is known as the ulceration stage. This stage is marked by penetration 
damage to nonkeratinized mucosa causing exposure of the lamina propria, a thin layer of 
connective tissue under the mucosa, due to the epithelial loss (Campos et al., 2014 & Panahi et 
al., 2016).  The ulceration stage is painful to patients because the epithelial loss results in nerve 
endings being exposed (Campos et al., 2014).  
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The final stage of the process is known as the healing stage.  The healing stage is one 
of the longest stages and can last 12 to 16 days. The duration of healing can be extended 
based on patient age, nutritional status, stage of oral hygiene and health, oncological treatments 
given, renal and hepatic functions (Cidon, 2018 & Panahi et al., 2016).  This stage is marked by 
lesion resolution, due to the submucosal extracellular matrix triggering that leads to cell 
proliferation, migration, and differentiation, healing the ulcers from the margins (Campos et al., 
2014 & Panahi et al., 2016).  Moslemi et al., (2014) noted that zinc is an important component of 
wound healing due to its anti-inflammatory effects, immune system modulator properties, and a 
necessity for synthesis of DNA.   
Oncological treatments increase the risk of OM through the production of tremendous 
amounts of reactive oxygen species.  It is estimated that at least 40% of patients receiving any 
oncological treatment will develop OM, while individuals receiving high doses of chemotherapy 
or radiotherapy of the head and neck will inevitably develop this condition (Campos et al., 2014; 
Eilers et al., 2014 & Panahi et al., 2016).  Other factors that put a patient at risk for developing 
this condition include age, poor oral hygiene, impaired salivary function, neutropenia, and use of 
alcohol and tobacco (Eilers et al., 2014; Farrington, Cullen, & Dawson, 2013 & Panahi et al., 
2016).  It has also been proposed that genetic factors can increase the risk of OM (Eilers et al., 
2014 & Panahi et al., 2016). 
Prognosis of Oral Mucositis 
The development of OM puts individuals at risk to develop treatment-related 
complications.  The most life threating condition is the development of bacteremia or sepsis 
related to bacteria entering through the lamina propria and invading the vascular walls (Campos 
et al., 2014; Eilers et al., 2014; Moslemi, Babaee, Damavandi, Pourghasem & Moghadamnia, 
2014; Obeid, 2018).  Individuals with OM are also at risk for developing complications related to 
malnutrition.  Ulcerations within the mouth and throat mark the ulceration stage of OM, limiting 
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the ability for oral intake due to pain and discomfort (Cullen et al., 2018; Moslemi et al., 2014; 
Obeid, 2018; Yarom et al., 2013).   
Poorer outcomes related to withholding oncological treatments occur in patients who 
develop OM.  Lee (2013) notes that is common for physicians to halt cancer treatments in 
attempts to lessen the oral pain and allow a period of healing.  For patients receiving 
radiological interventions, development of OM can lead to less than optimal treatment due to 
reduced radiation dosages which negatively impacts survivorship (Cullen et al., 2018; Eilers et 
al., 2014; Moslemi et al., 2014 & Obeid, 2018).  Other symptoms include xerostomia (dry 
mouth), fungal, and viral infections, impaired speech, and impaired swallowing (Cidon, 2018; 
Cullen et al., 2018; Eilers et al., 2014 & Slade, 2017).   
For individuals receiving oncological treatments, pain can reduce a patient’s quality of 
life.  In the early stages of OM, pain occurs along with erythema and swelling and increases if 
the condition advances to ulcerations (Cidon, 2018 & Eilers et al., 2014).  Pain is noted to be 
one of the factors that delays or reduces oncological treatments (Lee, 2015 & Cullen et al., 
2018).  Pain can also reduce the individual’s quality of life (Da Cruz Campos et al., 2014; Huang 
et al., 2017; Lee, 2013; Obeid, 2018 & Yarom et al., 2013).  Difficulties affect individual’s ability 
to speak, swallow, and taste occur during an acute episode of OM (Cidon, 2018; Eilers et al., 
2014 & Moslemi et al., 2014).  
Financial Implications of Oral Mucositis 
The development of OM can incur additional cost to individuals.  In 2013, it was noted 
that the average price for individuals who developed OM was $1,700 depending on severity 
(Eilers et al., 2013).  Individuals who experience secondary infections, sepsis, or who require 
nutritional support are all at risk for incurring higher costs related to hospitalization (Eilers et al., 
2014, Da Cruze Campos, 2018 & Slade, 2018).  Examples of other ways that OM can become a 
costly condition includes missed work days and expenses related to additional medication and 
treatments.  
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Standardized Assessment and Diagnosis of Oral Mucositis 
No universal clinical standard exists when assessing OM. Subjective qualities of OM that 
can be significant patient concerns that affect the quality of life, are omitted in many objective 
tools designed to evaluate oral mucosa.  Researchers conducting a systematic review of oral 
assessment instruments to find one appropriate for use in the pediatric and young teen 
populations noted there were 54 oral assessment tools at the time of their study, many of them 
untested for reliability and validity (Gibson et al., 2010).  Most scales are noted to be objective. 
However, objectivity cannot be absolute due to human interpretation. 
Individual disciplines often have their scale of preference (Panahi et al., 2016).  One of 
the most frequently used tools is the World Health Organization (WHO) Oral Mucositis Grading 
Scale (Gibson et al., 2010 & Panahi et al., 2016). This tool measures soreness with or without 
erythema, ulcers, if a patient can swallow solid food, and if alimentation is possible. Although 
pain is a distressing concern for individuals experiencing OM, it is often omitted from objective 
OM assessment tools. Use of patient-reported subjective tools is suggested to capture this 
phenomenon (Cullen et al., 2018; Obeid, 2018 & Slade, 2017).   
Another standardized assessment tool that has been used to measure the subjective 
effects OM is the Patient Reported Oral Mucositis Symptom (PROMS) survey. This tool 
measures mouth pain, speaking difficulties, and restriction of speech related to mouth sores 
(Kushner et al., 2008). The PROMS has some important advantages over other OM 
assessment tools, including measuring oral mucositis from the patient perspective.  Use of this 
tool can allow the evaluation of both preventive or palliative treatment for OM, which is 
appropriate for this evidence-based project (Kushner et al, 2008).    
Statement of the Problem  
 Data supporting the need for the project. The prevalence of OM in patients receiving 
treatment is 40-80% of those undergoing oncological treatments with some cancer treatments 
posing a higher risk up to 100% (Campos et al., 2014 & Panahi et al., 2016).  If OM progresses 
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to the ulceration stage, patients are at risk for life threatening infection such as systemic sepsis 
(Yarom et al., 2013). It is important to that that greater than one-third of the United States 
population will be diagnosed with cancer sometime in their life, some of which will require 
treatments that are linked to the development of OM (NCI, 2018).  Oncological treatments 
aimed at treating cancer can cause OM which is related to poorer patient outcomes, including 
malnutrition, dehydration, pain, difficulty communicating, infections of the oral cavity, and sepsis.  
Nursing professionals should understand how to prevent or reduce the effects of OM in a family 
practice setting. Moreover, these interventions should be effective, inexpensive, readily 
available, and easily transferable to the patient’s home setting.  
 There are extensive studies that look at methods to prevent OM, however they are 
generally limited to head and neck cancer patients receiving oncological treatments due to OM 
developing nearly 100% of cases (Eilers et al., 2014).  There is limited research on if prevention 
and symptom reduction is possible across a wide verity of cancer types.  Ideally, this evidence-
based project will explore if methods of prevention or symptom reduction are applicable to a 
wider patient base.   
Additionally, people affected with OM often suffer from worse clinical outcomes.  The 
development of OM can result in the need to reduce treatment doses, which then negatively 
impacts survivorship (Cullen, 2018).  Quality of life is also negatively impacted by OM, due to 
the pain and the impact on diet (Cullen et al., 2018 & Yarom, 2013).   
The clinical agency needs for the project.  The clinical agency in which this project 
was implemented identified an increasing awareness of the need for better oral mucositis 
prevention and care. This need was described by patients, caregivers, and office staff. The EBP 
project arose from the understanding that it is possible to reduce the negative impact of OM on 
individual’s quality of life while undergoing oncological treatments.  
Providers at the clinical agency accepted this project with the understanding that oral 
care and assessment at the clinical agency was inconsistently provided and may not be based 
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on the most relevant evidence.  Data about OM prevalence was difficult to find due to lack of 
consistency in charting across providers and no agreed upon scale of OM measurement.  For 
example, one physician charted narrative subjective information provided by a patient while 
another provider documented objective findings without providing the patient experience.  The 
office had no formal oral care protocol in place, and there was no standardized patient 
education about OM prevention or management.  
Purpose of the Evidence-Based Practice Project 
 Oral mucositis is a distressing side effect that can occur when individuals receive 
oncological treatments, resulting in decreased quality of life, poorer outcomes, and increased 
risk for adverse effects.  An extensive review of the literature has been performed to determine 
methods to prevent or reduce the impact of OM.  The purpose of this project was to examine the 
effect of establishing an oral care protocol as the baseline standard of care, then adding zinc 
sulfate supplementation to determine if it reduced the prevalence and/or severity of OM within 
the project setting.   Additionally, a patient-reported scale that measured the subjective OM 
experience, the PROMS survey, was identified and implemented to standardize the assessment 
and diagnosis of OM. 
The harmful effects of OM can be avoided or minimized with the implementation of an 
oral care protocol that includes zinc sulfate supplementation. Oral care is a low-cost intervention 
that can be helpful in the prevention of OM (Farrington et al., 2013 & McGuire et al., 2013).  
While there is not a universal oral care protocol recommendation in current clinical practice 
guidelines, empirical evidence from single studies suggests that a standardized oral care 
protocol within a facility can prevent or reduce the duration and severity of OM (Carvalho et al., 
2018; Eilers et al., 2014; Farrington et al., 2013 & McGuire et al., 2013).  Even though universal 
oral care protocols do not exist, recommendations include that the structure of the protocol 
should be clear and contain information about oral rinses, include a suggested frequency with 
which to perform oral care, and have easy to read instructions (Cidon, 2018 & Huang et al., 
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2018). Knowledgeable medical staff addressing oral care, assessing for signs and symptoms of 
OM and providing education to the individual about OM are also noted to be beneficial (Cullen 
et al., 2018; Da Cruz Compos et al., 2014 & Obeid, 2018).   
There is supportive evidence that zinc sulfate can help prevent or reduce the duration of 
OM in patients receiving oncological treatments.  In a meta-analysis looking at whether mineral 
derivatives helped prevent or reduce the symptoms of OM, data supported that zinc sulfate was 
helpful (Lee, 2015).  In a systematic review of various types of studies, it was noted that zinc 
sulfate as a supplement might help prevent OM in individuals with oral cancers (Yarom et al., 
2013).  Moslemi et al., (2014) conducted a study where individuals were given zinc sulfate and 
found that it reduced oropharyngeal mucositis and delayed the initiation of oral mucositis.   
Formation of an EBP oral care protocol with the addition of zinc sulfate supplementation may be 
beneficial in preventing or reducing the severity of OM.  Oral care protocols should be structured 
and teachable to both individuals receiving oncological treatments and the staff responsible for 
the administration of such.  Assessment tools should be consistent throughout treatment with 
oncological interventions.   
Anticipated effects are that the use of zinc sulfate, along with an oral care protocol, will 
prevent or reduce the severity of OM when compared to individuals who received oral care 
protocol education as a standard of care, reducing the effects of OM on the quality of life as 
measured by the subjective tools. The expected outcome is that patients receiving zinc will 
experience few distressing symptoms than individuals receiving the standard of care.   
 The PICOT question developed to guide the EBP project and develop a systematic 
approach was “In patients receiving oncological treatments, does an oral care protocol with zinc 
sulfate supplementation, compared to the standard of care (oral protocol alone), reduce 
complications related to oral mucositis as measured by a patient-reported assessment tool over 
a six week period?” 
The significance of the EBP Project 
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 For patients receiving oncological treatments, OM can be a distressing symptom.  Best 
practices indicate possible measures that can help prevent or reduce the severity of OM.  Not 
only will this improve quality of life for patients receiving oncological treatments, but it may also 
reduce life-threatening sequelae. The results of this EBP project may be useful in other areas 
such as radiology centers, inpatient hospital units that administer oncological treatments, and 
family practice.  Other facilities that manage oncological treatment may be able to use these 
results to reduce patient distress and improve survival outcomes.  This project was designed to 
apply EBP that focuses on patient quality of life. 
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CHAPTER 2 
 Oral mucositis (OM) is an adverse effect that often occurs in individuals receiving 
treatment for cancer that can compromise quality of life (Eilers, Harris, Henry & Johnson, 2014). 
OM is a complex inflammatory process that can progress to ulcerative lesions which may allow 
micro-organisms normally present in the oral cavity to enter the bloodstream resulting in life-
threating infections (Collen et al., 2018; Eilers et al., 2014).  The occurrence rate of this 
condition is estimated to be about 40% of individuals receiving chemotherapy and up to 100% of 
individuals receiving high-dose chemotherapy, radiation or both (Eilers et al., 2014; Harada et 
al., 2016).  OM is the most common cause of non-hematological complications and morbidity in 
individuals undergoing oncological treatments (Campos et. al, 2014).  This chapter describes 
the theoretical background and strength and quality of evidence for implementing selected 
interventions to manage OM. A model to guide the implementation of these interventions will 
also be described.  
THEORETICAL FRAMEWORK, EBP MODEL AND REVIEW OF THE LITERATURE 
Theoretical Framework 
 Self-care is identified as actions individuals and caregivers take for themselves and 
others to stay fit, manage long term conditions and maintain health and well-being (Williams, 
Mowlazadeh, Sisler, & Williams, 2015). Health can be conceptualized as simultaneously 
subjective, objective, comparative, classificatory, holistic, and/or a process occurring over time 
(Griffin, 2018).  Because health is a highly multi-faceted construct, self-care is highly variable 
and individualized across demographics. Furthermore, self-care needs depend on societal 
values, including concepts of what is required for physical, emotional, mental, spiritual and 
social wellbeing (Griffin, 2018).   
Self-care can be regarded in both positive and negative aspects.  Self-care examples 
that carry positive implications include exercise, lifestyle change, nutrition, using prescribed 
medications, biological treatments and creation of meaningful relationships (Finley & Sheppard, 
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2017; Williams et al., 2015).  Additionally, Self-care methods may also have negative 
connotations. In a study by Finley & Sheppard (2017) examining compassion fatigue in young 
oncology nurses some negative self-care skills included overindulging in alcohol, staying out 
late, binge-eating and sleep deprivation.  Williams and colleagues (2015) noted “do nothing” as 
a self-care skill that can have a negative impact on health (p. 579).  Inability to address self-care 
needs can result in poorer outcomes.  In a study of U.S. veterans receiving outpatient cancer 
treatment, researchers noted that the inability to develop self-care behaviors to manage side 
effects resulted in delay or termination of their treatment regimens (Williams et al., 2015).   
Research shows that self-care is a skill that can be built upon through preparatory 
education, cognitive restructuring, and building on current coping skills (Johnson, 2016). An 
example of preparatory education is educating individuals on what symptoms should be 
immediately reported and what to do in case of an emergency. Cognitive restructuring helps 
individuals identify maladaptive thought processes and dispute them through rational means. 
Enhancing current coping skills, such as humor or faith-based practices, is another example of 
self-care.   Self-care aimed at prevention of OM may help improve quality of life and increase 
survivorship (Cullen et al., 2018).   
The theory used to guide this project is Dorothea Orem’s Self-Care Nursing Theory. The 
theory of self-care postulates that individuals have the right and responsibility to care for 
themselves and maintain efforts towards health, and that nursing care is required when there is 
incapacity to meet the demands of self-care (Remeo, Deveraux, Detrick & Morris, 2018). The 
premise is composed of three interrelated concepts: self-care, self-care demands, and self-care 
agency (Griffin & Landers, 2014). Use of Orem’s self-care model allows nurses to judge a 
patient’s ability to meet their universal and developmental self-care requisites and address any 
health deviations. 
 Self-care. Orem defines self-care as comprised of the practice of activities that 
individuals initiate and perform throughout their life span in the interest of maintaining health, 
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functioning, development, and well-being by meeting self-care requisites (Orem, 2001).  Orem’s 
concept of self-care is rooted in an individual’s desire to preform care on their own behalf 
(Remeo, Deveraux, Detrick & Morris, 2018).  Blum (2014) notes common self-care activities 
include proper diet, exercise, and stress-reduction techniques.  An example of self-care is to 
learn how to take a blood pressure at home and take medication prescribed to control 
hypertension.  
 Self-care demands. Self-care demands are defined as varied degrees, and kinds, of 
care required to meet an individual’s need either at a specific point in time or across a duration 
of time (Remeo et al., 2018).  Self-care demands can be thought of as the care activities that 
are necessary to control or manage self-care requisites (Orem, 2001). Orem addresses several 
aspects of self-care through what is called self-care requisites (Fawcett & DeSanto-Madeya, 
2013).   
 Self-care requisites. Self-care requisites provide insight about actions that are known 
or assumed to be necessary in regulation of an aspect of human functioning or development 
along a continuum (Orem, 2001). Self-care requisites are best thought of as activities of daily 
living and apply to all individuals.  Self-care requisites are divided into three categories based on 
universal, developmental, and health deviations (Griffin & Landers, 2014).   
Universal self-care requisites are generalizable to all men, women, and children and 
address health goals that can be met through an individual’s ability to promote positive human 
responses across the life span (Remeo et al., 2018).  The universal self-care requisites are 
considered to be required by all people, regardless of age (Griffin & Landers, 2014).  The 
universal self-care requisites addressed in Orem’s theory, include: (a) the maintenance of 
sufficient intake of air, food, and water, (b) care associated with processes and excrements, (c) 
a balance between activities and rest, (d) balance between solitude and social interaction, (e) 
prevention of hazards to human life, human functioning and human well-being and (f) the 
promotion of human functioning and development within social groups (Orem, 2001).   
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 Developmental self-care requisites are those that are considered requisites to be met at 
a particular stage in development, which refers to learning to perform self-care in a consistent 
and effective manner (Griffin & Landers, 2014; Orem, 2001). These requisites are divided into 
three categories: self-care requisites that focus on conditions that are met with the assistance of 
dependent-care agents, an individual’s engagement in self-development, and ability to prevent 
or overcome conditions and life situations that can limit development. (Fawcett & DeSanto-
Madeya, 2013; Orem, 2001).  Developmental self-care requisites include providing and 
maintaining an environment that prevents both sensory deprivation and sensory overload, 
promoting positive mental health though deliberate efforts, and seeking to accept and explore 
feelings and emotions in relation to self, others, objects, and situations (Fawcett & DeSanto-
Madeya, 2013).  
 Health-deviation self-care requisites address the essential requirements that need to be 
met during ill-health (Griffin & Landers, 2014).  Two subcategories exist, one arising directly 
from disease, injury, disfigurement and disability with the other arising from the medical care 
measures that medical professionals preform or prescribe (Fawcett & DeSanto-Madeya, 2013).  
Examples of health-deviation self-care requisites include seeking out healthcare, being aware 
and attending to effects of pathological conditions such as seen with preventative care 
measures and learning to live with the effects of a chronic condition such as diabetes (Orem, 
2001).   
Self-care agency. Self-care agency addresses the individual’s ability to engage in self-
care (Orem, 2001).  Several conditioning factors can affect an individual’s ability to act as a self-
care agent including factors such as age, developmental state, health state, sociocultural 
orientation, and environmental factors (Fawcett & DeSanto-Madeya, 2013).  Self-care agency 
requires individuals to have sufficient power to complete self-care activities (Fawcett & 
DeSanto-Madeya, 2013). Research also shows that social support plays an important role in 
self-care agency. In a study among patients with a history of cardiac surgery, group participation 
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was shown to increase self-care agency through group social support (annual meetings), 
activities (planned physical activities), and reading newsletters (member-submitted stories and 
essays) (Noguchi-Watanabe, Yamamoto-Mitani, Arimoto, & Murashima, 2017). Orem (2001) 
believed that social support is an essential aspect of self-care agency because others can 
allocate power and other self-care resources to close the self-care gap for individuals who lack 
sufficient power and self-care agency on their own. Examples of individuals who can provide 
this social support include family members, neighbors, friends, social clubs and organizations, 
and healthcare professionals, particularly nurses.  
Therapeutic self-care demands. Therapeutic self-care demands consist of the care 
measures needed, at a specific time or over a duration of time, to meet all an individual’s known 
self-care requisites (Fawcett & DeSanto-Madeya, 2013).  These demands encompass all 
required regulatory care (Orem, 2001).  A clinical example that illustrates the concept of 
therapeutic self-care demand is the maintenance of the oral cavity while receiving oncological 
interventions.  The self-care gap in this example is the knowledge of techniques to ensure 
adequate oral hygiene, referred to as a self-care deficit.  Self-care deficit occurs when 
therapeutic self-care demands exceed self-care agency (Orem, 2001).  In the provided 
example, the individual receiving oncological care has a self-care deficit because they do not 
yet have the ability or knowledge to perform correct oral care.   
Nursing systems serve to address defects between self-care agency and therapeutic 
self-care (Griffin & Landers, 2014).  To address deficiencies, nurses deliberately act to design, 
plan, implement and evaluate the systems of therapeutic self-care through the nursing process 
(Fawcett & DeSanto-Madeya, 2013).  Nursing services can address self-care deficits through 
providing all of the essential care (i.e., a wholly compensatory system), providing some of the 
needed care (i.e., a partly compensatory system), or through cueing and prompting (i.e., a 
supportive-educative system; Griffin & Landers, 2014).  
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Application of Theoretical Framework to EBP Project.   
Self-care serves to motivate individuals to seek out medical assistance, carry out 
medically prescribed treatments, and modify the self-image to fit the current state of health 
(Griffin & Landers, 2014).  Self-care can be characterized according to specific clinical 
situations, such as undergoing oncological treatments. The flexible nature in which self-care can 
be defined makes Orem’s Self-Care Theory especially potent to use with individuals who may 
develop painful oral mucositis after receiving oncological treatments.  Since this EBP project is 
taking place in an outpatient cancer treatment setting, which requires participants to manage 
OM mainly on their own, their success will rely heavily on Orem’s educative-supportive nursing 
system to address self-care deficits.  
By including the self-care requisites within the theory, Orem addresses the importance of 
primary, secondary and tertiary care.  For example, an oral care protocol can be implemented to 
help prevent OM or reduce symptoms once the condition occurs.  The inclusion of requisites 
also makes the theory highly generalizable across demographics (Remeo et al., 2018).  When 
addressing health-deviation self-care requisites, research shows that individuals must be aware 
of discomforting or uncomforting effects of medical care measures (Fawcett & DeSanto-
Madeya, 2013).  Since oncological therapies are well known to cause numerous side effects, 
including OM, it will be imperative for nurses to prepare their patients for the development of OM 
proactively.  
Finally, this theory acknowledges the importance of situational life events, effects of age, 
developmental stage, gender, environment, learning style, and so forth as having effects on the 
ability to perform self-care (Fawcett & DeSanto-Madeya, 2013).  Since cancer treatment can 
occur at any time in the lifespan, Orem’s theory encourages that education is tailored to the 
developmental level of the client to maximize their self-care agency (Fawcett & DeSanto-
Madeya, 2013).  This is an appropriate topic to consider since the outpatient clinic addresses 
cancers that occur across the lifespan and treats a broad demographic.   
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Strengths and limitations of theoretical framework for EBP project.  Orem’s Self-
Care Theory is well suited for cancer care because it guides situational self-care to reduce 
symptoms, enhance recovery, and promote overall well-being. Since cancer treatment can 
cause OM, which can have devastating effects on patient comfort and cancer recovery, this 
theory can be directly applied to the development of interventions to prevent OM. It can be used 
to design patient education, which facilitates patient-directed self-care, as well as supportive 
and restorative nursing care. (Fawcett & DeSanto-Madeya, 2013).    
The primary limitation of this theory is that Orem focuses heavily on physical well-being, 
rather than emotional well-being. Because cancer has profound effects on all facets of health, 
including emotional health, this theory may be insufficient to develop nursing interventions 
geared toward enhancing emotional support in patients with cancer (Fawcett & DeSanto-
Madeya, 2013). Furthermore, there are differences in cancer types and the oncological 
treatments required, resulting in some client groups being healthy and relatively asymptomatic 
(physically well) while also needing treatment to eliminate the malignancy or prevent its 
metastasis to other sites (cancer requiring intervention). Within this type of patient, there seems 
to be two diametrically opposed levels of self-care needs. However, further examination of the 
Self-Care Theory reveals that, while there are no symptoms (thus no need for symptom-relief 
self-care), there is still a physical illness requiring medical, surgical, or radiological treatment. 
Therefore, management of the cancer will still require the nurse to intervene to enhance the 
patient’s self-care agency.  
Evidence-based Practice Model 
Evidence-based models serve as systematic frameworks to assimilate new evidence 
into nursing practice in an organized and methodical fashion.  For this EBP project the Johns 
Hopkins Nursing Evidenced-Based Practice Model (JHNEBP Model) was chosen. This model 
was initially developed in 2002 by a team of nurses and facility at the Johns Hopkins Hospital 
(JHH) to simplify the EBP process and allow easier transition of EBP to nurses within the clinical 
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setting (Melnyk & Fineout-Overholt, 2015).  Since its original publication, the model has been 
revised with the newest edition, the third, published in 2017 (Dang & Dearholt, 2017).  The most 
current model, used with permission, will serve as the framework for the EBP project presented. 
The JHNEBP Model is composed of an open system with three interrelated concepts: 
inquiry, practice, and learning. By having a model that is an open system, it allows and 
accommodates for both internal and external factors to be incorporated within the model.  
Internal factors include policies, organizational culture, values, believes, equipment, supplies, 
staffing, and offered services.  Examples of external factors include local, state, and federal 
regulations, accreditation bodies, and external stakeholders (Dang & Dearholt, 2017).  This 
makes the model highly adaptable across many care settings.   
The first three concepts addressed by the JHNEBP Model are inquiry, practice, and 
learning.  Inquiry is first step and it considered the starting point of EBP.  This phase is 
hallmarked by inquisitiveness to examine a question, collect information in light of a concern, 
problem, or issue.  It encourages addressing a problem and discovering solutions in novel and 
innovative ways.  Following inquiry, comes practice which is the transition of putting what is 
known into what is done.  Practice embraces the standards that are established by professional 
nursing organizations and help nurses operate within their scope of practice and meet 
professional performance standards.  The next phase is the learning, which is when information 
is passed on and the one learning can understand it. For the JHNEBP Model learning is 
considered an ongoing process, keeping up with new information, technologies, skills and 
clinical practices.  The JHNEBP Model holds learning as a lifelong process and project teams 
should be interprofessional and collaborative in nature (Dang & Dearholt, 2017).    
Once the process of inquiry has started, individuals or teams can start to seek out the 
best evidence to address a problem.  These groupings work systematically through the practice 
question that is being explored, the evidence concerning the practice, and then the transition 
into practice which is referred by acronym, PET.  Since the PET process is informed by practice 
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and an evolving understanding of solutions to the practice problem, new EBP processes can be 
triggered throughout this cycle (Dang & Dearholt, 2017).   
Application of EBP model to EBP project. The current EBP project will follow the 
inquiry-practice-learning process and PET principles advocated in the JHNEBP Model. Because 
this chapter is limited to understanding the underlying problem and identifying potential 
solutions, this section will focus on the inquiry stage of the inquiry-practice-learning process and 
the practice and evidence principles of the PET acronym. The practice and learning stages and 
transition principle of PET will be described in subsequent chapters.  
Inquiry and the practice problem. A problem-focused prompt was developed while 
working with a client who suffered from OM to a degree where admission to an acute care 
hospital was required for management of symptoms.  Upon discussions with interdisciplinary 
team members, including an oncology and hematology physician, cancer nurse navigator, and 
oncology staff nurses, it was determined that prevention measures for OM were largely 
unexplored.  Preventing OM for clients was considered an important priority and the project was 
approved by stakeholders who administered oncological therapies in an outpatient setting.  
After the problem was defined, there was a discussion about where the gap was 
between current practice and desired practice.  At the start of this project, there was no 
consistent information about whether OM could be prevented, and clients were provided 
minimal education on the topic. The compelling clinical question was then identified.  
To address all appropriate stakeholders, a multidisciplinary team was formed that 
consisted of an oncology physician, clinical office manager, and a nurse practitioner.  The team 
determined that at baseline there was no standard of care concerning OM and teaching was 
done inconsistently by point of care staff.   
Evidence. Once the practice problem was identified, an exhaustive literature search was 
performed to explore possible interventions to prevent and treat OM. This evidence will be 
described in greater detail later in this chapter. After evidence was collected, appraised for level 
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and quality, and summarized, it was determined that an oral care protocol needed to be 
implemented as standard of care and that zinc sulfate should be initiated on clients to prevent or 
reduce the effects of OM.   
Transition and learning. The transition plan will be described in chapter 3, along with the 
plan for evaluating the intervention. An explanation about what was learned through project 
implementation and evaluation will be provided in chapters 4 and 5.  
The JHNEBP Model serves as an excellent framework to guide implementation of the 
EBP from inquiry of about best practice to dissemination of a project.  The model guides users 
though a 19-step process and clearly explains what action is required to fulfil one step and 
move on to the next.  The model is flexible enough to be used in acute care settings, outpatient 
clinics, and other point of care areas. It encourages users to identify all stakeholders in a 
systematic fashion and provides detailed spreadsheets to help organize the data.  Using the 
JHNEBP Model to guide EBP project also helps establish the quality and grade of the data 
though comprehensive worksheets. This assisted in identifying high quality data that was useful 
for development of the protocol and clinical recommendations.  The model also provided 
guidance on how to synthesize the overall findings of the evidence and how data should be 
transitioned into practice (Dang & Dearholt, 2017). 
Strengths and limitations of EBP model for EBP project.  
The primary strength of the JHNEBP Model is that it has been widely and successfully 
used in a variety of clinical contexts and to solve numerous practice problems. One of the 
reasons for its success is that it provides guidance to interprofessional project teams through 
well-defined steps. Moreover, it is one of the most often-used EBP models in nursing practice, 
and examples of its application abound in the peer-reviewed literature. It is a model that allows 
for flexibility while still providing adequate guidance to ensure that an EBP project is 
successfully completed.  
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Limitations noted for the JHNEBP Model included that the tools for appraising evidence 
were lengthy and subjective, especially with lower levels of research. The nonlinear format of 
the model encourages new EBP projects to be developed out of current EBP projects that are in 
progress, which can create confusion (Dang & Dearholt, 2017).  There is no clear guideline on 
whether a new EBP project needs to be started or if the current one in progress can be 
modified.  For example, during the implementation phase of the oral care protocol, the oral care 
of clients with dentures requires special attention.  The JHNEBP Model provides little guidance 
about whether this should form a new EBP project altogether, or if the original oral care protocol 
should be adapted along the way to address the unique needs of clients who wear dentures.  
Despite these limitations, the JHNEBP Model provides a powerful set of user friendly 
tools that work to move evidence into practice. From development of the question, to literature 
critique and evaluation, to implementation and evaluation the tools systematically address each 
step of the process.  Additionally, this EBP model encourages users to concern both internal 
and external factors that the change might impact.  
Literature Search 
 A search for evidence-based literature was conducted in efforts to find the best available 
evidence related to the prevention of OM in adult clients receiving oncological treatments.  
Databases searched for evidence included (a) CINAHL, (b) MedLine, (c) Cochrane, (d) Joanna 
Briggs Institute (JBI), (e) Nursing & Allied Health Database, and (f) National Guidelines 
Clearinghouse.  In efforts to maintain consistency across the databases, terms used were “oral 
mucositis” and prevent* were used across all databases.  Additional search term of cancer OR 
chemo* was included in the MedLine, CINAHL, Nursing & Allied Health Database and National 
Guidelines Clearinghouse databases.  For the CINAHL database the word adult was added to 
search terms to assist in locating articles relevant to the population of the EBP project.  Citation 
chasing was also performed in efforts to locate the best available data.   
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 Inclusion criteria included studies that were (a) published between 2013 and 2018, (b) 
written in English, (c) peer reviewed and (d) focused on efforts to prevent OM.  Studies that 
were excluded included (a) interventions that focused on pediatric populations, (b) prevention of 
OM using one specific chemotherapy agent, (c) studies that used drugs not approved for use in 
the United States, (d) failure to include results or recommendations and (e) studies that formed 
recommendations that were not based on timely data at the time of publication.  
Search results. Complete search results from all data bases are depicted in table 2.1  
CINAHL yielded a total of 35 articles, 27 of which were excluded by title alone.  Four additional 
titles were eliminated after abstract review due to irrelevance to the purpose of this review, the 
remaining 4 articles were included in the review for further analysis.  MedLine produced 270 
results, after the removal of 3 duplicates, 255 articles were eliminated on title alone.  The 
remaining 12 articles underwent abstract review and resulted in the elimination of 7 more article, 
leaving a total of 5 included in the review.  A search was conducted in the Cochrane database 
and yielded a total of 5 results, 3 were irrelevant to the purpose of this review, and after abstract 
review of the remaining 2 articles, neither were determined to be appropriate for use in the 
project.   Joanna Briggs Institute revealed 35 results with 6 articles reviewed, 2 were selected 
for inclusion. The Nursing & Allied Health Database yielded 18 results, 3 were reviewed but 
none were selected for inclusion.  Finally, National Guidelines Clearinghouse was searched, 
revealed 16 results, after eliminating 15 due to irrelevancy, 1 underwent review and was not 
acceptable for inclusion.  A detailed review of cited literature yielded a total of 5 pieces of 
evidence that were chased and all 5 were reviewed with 2 meeting inclusion perimeters.  
Altogether, 13 unique pieces of evidence were included. 
Levels of evidence. Evidence for this EBP was assigned by following the stipulations 
presented in the evidence level and quality guide found in Appendix D of ©The Johns Hopkins  
Hospital/The John Hopkins University nursing EBP guide (Dang & Dearholt, 2017).  Levels of 
evidence fall into five categories, listed as levels I – V.  The tool describes level I evidence as  
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Table 2.1 
Studies obtained from databases 
 
 
  
Database Initial Articles for 
Review 
Duplicates  Abstracts 
Reviewed 
Included in 
Review  
CINAHL 
 
35 0 8 4 
MedLine 
 
270 3 12 5 
Cochrane 
 
5 0 2 0 
JBI 
 
35 0 6 2 
Nursing & Allied 
Health Database 
 
18 0 3 0 
National 
Guidelines 
Clearing House 
 
16 0 1 0 
Chased 
 
5 0 5 2 
Total    13 
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experimental, randomized control trails (RCTs), explanatory mixed method studies that include 
only other level I quantitative data, and systematic reviews of RTCs, with or without meta-
analysis.  Level II studies include individual quasi-experimental reports and mixed method  
designs that include only other level II studies, systematic reviews that are a combination of 
RCTs, quasi-experimental studies, or quasi-experimental studies alone, with or without meta-
analysis.  Level III studies are nonexperimental studies, systematic reviews including a  
combination of RCTs, quasi-experimental and nonexperimental studies, or nonexperimental 
studies alone with or without meta-analysis, exploratory, convergent, or multiphasic mixed 
method studies, explanatory mixed method designs that include only other level III quantitative 
studies and qualitative studies with meta-synthesis.  Level IV data includes opinions of 
respected authorities, opinions of nationally recognized expert committees, or consensus panels 
based on scientific evidence.  This level provides inclusion of clinical practice guidelines, 
consensus panels, and position statements.  The lowest level of evidence provided by this 
method is level V, which is based on experiential and non-research evidence, including 
integrative reviews, literature reviews, quality improvement, programs, or financial evaluations, 
case reports, and opinions of naturally recognized experts based on experiential evidence 
(Dang & Dearholt, 2017). 
 Appraisal of relevant evidence.  Quality ratings for the appraisal of evidence for each 
research article were assigned based on the quality ratings system found in Appendix D of 
©The Johns Hopkins Hospital/The John Hopkins University EBP nursing guide (Dang & 
Dearholt, 2017).  Quality ratings are assigned as A, A/B, B, or C to each article.  The assigned 
grade of A indicates a research article is considered high quality and has features such as being 
consistent, having generalizable results, and making consistent recommendations based on 
exhaustive literature review that includes scientific evidence at level I.  For level IV a grade of A 
indicates that materials were officially sponsored by professional, public, or private 
organizations, systematic literature search was completed, results were reported with sufficient 
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numbers of well-designed studies, and able to draw definitive conclusion.  Level V assignment 
of grade A indicates clear aims and objectives, consistent results across various settings, 
evaluation of programs have been used, and definite conclusions and recommendations made 
with reference to scientific evidence (Dang & Dearholt, 2017).   
At evidence levels II and III, the grade A/B indicates high/good quality studies, that 
discusses efforts made to evaluate the quality of the data, including transparency, diligence, 
verification, self-reflection, participant-driving inquiry and insightful interpretation.  The A/B grade 
requires evidence of some or all of the qualities that are listed, though no calculated formula is 
provided by the tool (Dang & Dearholt, 2017).  
Evidence graded at B indicates that the study is considered good quality.  Features of 
good quality evidence included reasonably consistent results, sufficient sample sizes, some 
control, definitive conclusions, reasonable recommendations, and some reference to scientific 
reference at level I.  For levels IV and V, good quality studies are expected to meet most of the 
features of grade A, but with reduced focus on key components.  At grade B it can be expected 
that fairly definitive conclusions can be drawn, expertise is evidence, and some reference to 
scientific evidence is made (Dang & Dearholt, 2017). 
Each level of evidence has a corresponding grade of C and these are considered low 
quality or majorly flawed studies.  In this category, studies have little evidence, are 
inconsistence, or can not draw conclusions and lack many of the features noted for higher 
grading.  The grade of C indicates that poorly defined improvement, evidence not revised within 
the past five years, or small sample size (Dang & Dearholt, 2017).  In the following selection 
analysis and quality of each piece of evidence will be discussed (See Evidence Summary, Table 
2.2). 
Level I Evidence. Lee (2015) conducted a systematic review of RCTs with meta-
analysis reviewing the effects of mineral derivatives, including zinc sulfate, in preventing or 
alleviating OM during oncological treatments.  Their search was comprehensive including RCTs 
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from five large databases and specific keywords used in each database.  Inclusion and 
exclusion criteria are clearly stated and applied to search studies appropriately.  Lee (2015) 
provides a flow diagram that included the number of studies eliminated at each level of review.  
Sixteen studies were included in the meta-analysis and were analyzed for quality using 
Cochrane Collaboration guidelines. Trial and patient characteristics were also reviewed, finding 
a 1:2 female-to-male ratio in adults, with a mean age of 49.  Other demographic information 
included percentile breakdowns of regions that the studies took place, percentages of 
oncological treatments, common chemotherapy combinations that appeared across the studies, 
and common radiation maximums. All data was pooled by outcome and results examined: Peak 
OM incidence, OM duration, time to OM onset, pain incidence, and analgesic use. Statistically 
significant findings were noted with participants who took mineral derivatives had reduced 
symptoms than those without treatment (g = −0.47, 95% CI −0.7 to −0.2, p = 0.0006, I2 =61%). 
Additionally, the time of OM onset was significantly delayed in those that took mineral 
derivatives (g = −0.5, 95% CI−0.8 to−0.2, p = 0.0002, I2 = 35%).  One limitation addressed was 
many of the RCTs were only conducted at single locations, making generalization questionable. 
High heterogeneity exists in this study due to diverse therapies and different OM measurement 
tools.  Results suggest positive effects of mineral derivatives, chiefly zinc sulfate, in prevention 
and treatment of OM (Lee, 2015).  Quality rating for this data is A due to the consistency, 
sufficient sample size at meta-analysis level, and strong recommendations based on 
comprehensive literature review.   
Moslemi, Damavandi, Pourghasem, and Moghadamnia (2014) performed a randomized 
control trial in a medical university department of radiotherapy to evaluate the potential benefits 
of zinc sulfate in the prevention of OM in head and neck cancer patients.  The literature review 
was current at the time of the study.  Research type is described as a phase III, double blind, 
placebo-controlled RCT. Forty patients diagnosed with head and neck cancer were randomly 
divided into two equal groups, with one group receiving zinc sulfate while the other received the 
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placebo capsules which were filled with starch and designed to appear identical as capsules 
used in the experimental group. The intervention group received 30 mg of zinc sulfate starting 
10 days before oncological treatment and 14 days after oncological treatment ended, while the 
control group received a starch filled placebo. No characteristic or demographic differences 
were noted between groups. Exclusion criteria were described in detail.  Data were collected 
using the well-validated Oral Mucositis Assessment Scale (OMAS).  Results were presented at 
various points throughout the treatment, including known peak times of OM.  In weeks 2 through 
7, eight patients scored lower on the OMAS scale in the zinc group, than they did the placebo 
group (p<0.003), indicating that patients in the treatment group had less severe OM.  Limitations 
were omitted from the study, but small sample size and limited to one cancer type are noted. 
This study supported the hypothesis that use of zinc sulfate can reduce the severity of OM in 
groups receiving radiation (Moslemi et al.,2014). Quality rating of B was assigned to this study, 
due to small sample size for the study design.   
 In a randomized controlled trial conducted by Huang et al., (2018) a study exploring the 
effectiveness of a saline mouth rinse regimen and education program on OM symptoms and 
quality of life (QOL) in patients receiving oncological treatments. The study was conducted at a 
cancer center in northern Taiwan.  Sample size grouping was not described.  Participants were 
randomly divided into experimental or control group by casting of lots. Patients in the two groups 
differed in marital status, and this variation may have influenced the independent variable 
because of the differences between the physical and social-emotional quality of life could 
marital status may have had an influence but was not accounted for in the study. The 
intervention group was taught mouth care skills, provided face to face education, and given 
supportive care consisting of assessing patient concerns, emotional support, evaluation and 
response to the saline mouth care, and answering questions. Control group received the 
standard of care, which included education of mouthwashes made from boiled water for three to  
four-hour intervals after meals. Measurements were recorded using the World Health  
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Table 2.2 Evidence summary 
Citation, Level of 
Evidence 
 
Study 
Design 
Setting, 
Sample 
Purpose Measurement Results Limitations Conclusion, 
Recommenda
tions 
Carvalho, C. G., 
Medeiros-Filho, J. B., 
& Ferreira, M. C. 
(2018). Guide for 
health professionals 
addressing oral care 
for individuals in 
oncological treatment 
based on scientific 
evidence. Supportive 
Care in Cancer, 
26(8), 2651-2661. 
doi:10.1007/s00520-
018-4111-7 
 
Level I, Grade B  
Systematic 
reviews of 
randomize
d clinical 
trails 
(RCTs) 
and RCTs 
Incorporated 
data from 17 
Systematic 
reviews/meta
-analyses of 
RCTs of high 
quality or 
well 
conduction 
RCTs or 
RCTs with a 
very low and 
low risk of 
bias  
 
37 RCTs 
with diverse 
designs 
To determine 
the best 
evidence 
based oral 
care for 
patient 
receiving 
oncological 
treatments 
Multiple 
studies 
looking at 
preventive and 
therapeutic 
conduct for 
oral 
complications 
and 
addressing 
oral 
assessment, 
professional 
and home oral 
care 
Before 
oncological 
treatments 
oral hygiene 
for home 
should be 
taught, 
brushing 3x 
daily with 
ultra-soft 
burhs and 
fluoride 
toothpaste 
and dental 
floss  
 
Lubrication 
and 
hydration of 
the oral 
mucosa in 
cases of 
xerostomia 
 
Periodic 
evaluation 
during and 
after 
oncological 
treatments 
and oral care 
No 
standard 
oral 
protocol 
was able to 
be 
developed 
Oral care 
minimizes 
oral 
complications 
during 
oncological 
treatments 
 
Assessment 
of oral 
condition is 
important 
during 
oncological 
treatments 
ORAL MUCOSITITS PREVENTION   28 
 
 
protocols can 
help prevent 
or minimize 
OM 
Cidon, E. U. (2018). 
Chemotherapy 
induced oral 
mucositis: prevention 
is possible. Chinese 
Clinical Oncology, 
7(1), 6. 
doi:10.21037/cco.201
7.10.01 
 
Level II, Grade C 
quasi-
experiment
al cohort 
design 
Medical 
oncology 
hospital in 
Bournemout
h, UK 
 
N=68  
 
Female 
breast 
cancer 
patients 
undergoing 
neoadjuvant 
or adjuvant 
treatment, 
who 
experienced 
OM during 
the past 
cycle 
 
 
To explore if 
a special 
mouthwash 
(combination 
mouthwash 
with anti-
inflammatori
es, antifungal 
and saline 
water) could 
help reduce 
the effects of 
OM in a 
patient 
population 
who had 
previously 
experienced 
OM during 
their 
treatment 
cycle 
Patient survey 
consisting of 7 
yes/no 
questions 
concerning OM  
 
Medical 
oncologist 
assessment 
using criteria 
stabled by 
WHO 
 
A binomial 
test 
concluded 
probability of 
grade 2–3 
OM after 
using this 
mouthwash 
was lower 
P=0.000087 
(1-sided). 
And the 
probability of 
grade 2 OM 
was 
P=0.000015 
(1-sided) 
Data was 
limited to a 
female 
population 
and 
specific 
chemo 
regiments 
to treat 
breast 
cancer 
 
All 
participates 
were 
previously 
educated 
but 
protocol is 
not 
described 
 
Non-
validated 
tool used 
to collect 
patient 
information  
 
Data not 
inclusive 
as to why 
The special 
mouthwash, 
when used 3 
times daily 
starting 3 
days before 
expected 
episode of 
OM was 
effective in 
reducing the 
severity of 
OM in women 
who were 
already in 
good dental 
health and 
had 
previously 
been 
educated on 
oral care  
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ingredients 
to special 
mouthwash 
were 
chosen 
and 
unclear if 
one 
ingredient 
of it was 
superior to 
others 
Cullen, L., Baumler, 
S., Farrington, M., 
Dawson, C., 
Folkmann, P., & 
Brenner, L. (2018). 
Oral care for head 
and neck cancer 
symptom 
management: 
Piloting an evidence-
based practice 
change at a radiation 
oncology center. AJN 
American Journal of 
Nursing, 118(1), 24-
45. 
 
Level III, Grade A 
 
Descriptive 
study  
One 
radiation 
oncology 
center 
 
N=28 (n=23 
responded) 
clinicians, 
and patients 
N=105 (n=20 
usual care 
prior to 
intervention, 
n=85 
intervention)  
To 
Implement 
and study 
the 
effectiveness 
of EBP 
change 
designed to 
reduce the 
severity of 
oral 
mucositis in 
adults 
receiving 
radiation 
treatments 
for head and 
neck cancers 
Pre and 
posttest of 
clinician 
knowledge on 
4-point Likert 
scale before 
and after 
intervention  
 
Patient survey 
with questions 
concerning 
oral care 
practices, 
patient 
perceptions 
about oral care 
rated on a 4-
point Likert 
scale and 
subjective oral 
mucositis 
symptoms 
rated on an 11-
Clinicians 
scores 
improved  
 
N=29 (n=20) 
preimplemen
tation 
 
Correct 
response to 
knowledge 
assemsent 
from 71% 
preimplemen
tation to 80% 
postimpleme
ntation 
 
Intervention 
patient 
reported less 
severity than 
usual care 
patients in 
Study 
focused on 
a limited 
cancer 
type 
 
Preformed 
only in one 
clinical, 
generalizati
on may not 
be possible 
 
All material 
needed for 
the study 
were 
provided to 
the 
patients  
Implementatio
n of an oral 
care protocol 
reduces the 
patient-
reported 
perceptions of 
complications 
due to OM 
 
Implementatio
n of an oral 
care protocol 
can improve 
clinician 
knowledge 
and assist in 
changing 
towards EBP 
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point Likert 
scale collected 
prior to 
initiation of 
treatment, 4-5 
week of 
treatment, and 
one month 
after treatment 
various 
symptoms: 
mouth and 
throat 
soreness 
(3.9 versus 
5), difficulty 
swallowing 
(4 versus 
5.6), difficulty 
eating (4.9 
versus 5.9), 
and difficulty 
talking (2.9 
versus 4), 
less difficulty 
with 
xerostomia 
(3.1 versus 
4.1) 
 
da Cruz Campos, M. 
I., Campos, N.C., 
Aarestrup, F.M., & 
Aarestrup, B. J. 
(2014). Oral 
mucositis in cancer 
treatment: Natural 
history, prevention 
and treatment. 
Molecular and 
Clinical Oncology, 
2(3), 337-340.  doi: 
10.3892/mco.2014.2
53 
 
Literature 
review 
29 articles 
between 
1994 and 
2013  
To review 
OM, it’s 
causes and 
treatment in 
professional 
settings 
PubMed, 
Lilacs, and 
MedLine used 
to retrieve 
articles, using 
keywords of 
oral mucositis, 
prevention and 
control, 
pharmacologic
al effects 
and 
immunosuppre
ssive agents 
Professional 
oral 
examination 
should be 
performed 
prior to 
initiation of 
oncological 
treatments 
 
Preventive 
oral care 
program 
should be 
followed to 
Inclusion 
and 
exclusion 
criteria not 
clearly 
described  
Patients may 
benefit from 
professional 
instruction of 
oral hygiene  
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Level V, Grade B reduce the 
complication 
of 
oncological 
treatments  
 
 
Eilers, J., Harris, D., 
Henry, K., & 
Johnson, L. A. 
(2014). Evidence-
based interventions 
for cancer treatment-
related mucositis: 
Putting evidence into 
practice. Clinical 
Journal of Oncology 
Nursing, 18(6) 80-96. 
doi:10.1188/14.CJON
.S3.80-96 
 
Level V, Grade A 
Literature 
review 
104 
publications 
from 2008 to 
2013  
Review of 
evidenced-
based 
interventions 
for OM and 
develop 
guidelines for 
nursing 
interventions 
PubMed was 
searched for 
Mucositis[ti] 
OR 
Mucositis[majr] 
OR “oral 
complication*” 
with 635 
articles yielded 
 
CINAHL 
search 
inclused (MM 
“Mucositis” OR 
MM 
“Stomatitis” 
OR TI 
Mucositis 
OR TI 
stomatitis OR 
“oral 
complication*”) 
AND (cancer 
OR neoplasms 
OR oncolog* 
OR 
chemotherap*) 
with 338 
articles yielded 
Recommend
ed for 
practice: 
cryotherapy, 
low-level 
laser 
therapy, oral 
care 
protocols, 
palifermin, 
sodium 
bicarbonate 
mouth 
rinses. 
 
Likely to be 
effective: 
Benzydamin
e rinses, 
Lactobacillus 
lozenges, 
prophylactic 
chlorhexidine 
mouth rinses 
 
Effectiveness 
not 
established 
Recommen
ded for 
practice is 
not 
applicable 
to 
generalize
d cancer 
patients or 
can only be 
used with 
limited 
chemother
apies.   
 
Expense 
limits the 
effectivene
ss of the 
recommen
dations  
Oral care 
protocols that 
provide 
frequent oral 
hygiene, 
prophylactic 
mouth rinses, 
and routine 
assessment 
can help 
decrease the 
incidence, 
duration and 
severity of 
OM. 
 
Structure and 
components 
of oral care 
are important 
 
Sodium 
bicarbonate 
month rinses 
are 
recommende
d. 
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After review 
only 104 met 
inclusion 
perimeters   
in 46 
interventions 
Effectiveness 
unlikely for 
Isegana, 
traumell S, 
Wob-Mugos 
E 
 
Not 
recommende
d: 
Chlorhexidin
e as a 
nonprophyla
ctic, 
Sucralfate   
Zinc or Zinc 
supplements 
noted as 
effectiveness 
not 
established.    
Farrington, M., 
Cullen, L., & Dawson, 
C. (2013). Evidence-
based oral care for 
oral mucositis. ORL-
Head and Neck 
Nursing: Official 
Journal of The 
Society of 
Otorhinolaryngology 
and Head-Neck 
Nurses, 31(3), 6-15.                                            
 
 
Level V; Grade A 
Literature 
review 
Large 
academic 
medical 
center, all 
nurses 
Development 
and 
implementati
on 
of an oral 
care protocol 
for use in 
adult and 
pediatric 
populations   
Educational 
PowerPoint 
with new oral 
care policy for 
use in unit in-
services and 
computer-
based training.    
3-month 
post-
implementati
on 
knowledge 
assessment 
nurses 
(n=117)  
 
Topic 
knowledge:  
100% - use 
of soft 
toothbrushes 
 
97% Biotene 
toothpaste 
 
Preformed 
at one 
facility  
 
No pre-
test, 
posttest 
only 
 
 
Prevention of 
OM should be 
addressed by 
routine oral 
care using 
evidenced 
based 
products  
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55% correct 
assessment 
knowledge 
56% correct 
flossing 
knowledge 
 
46% correct 
lip care  
 
52% correct 
rinses for 
OM 
Huang, B., Wu, S., 
Lin, C., Fan, K., 
Chang, J. T., & Chen, 
S. (2018). The 
effectiveness of a 
saline mouth rinse 
regimen and 
education 
programme on 
radiation‐induced oral 
mucositis and quality 
of life in oral cavity 
cancer patients: A 
randomised 
controlled trial. 
European Journal of 
Cancer Care, 27(2), 
1-10. 
doi:10.1111/ecc.1281
9 
 
Level I, Grade B 
RCT Cancer 
center of a 
medical 
center in 
northern 
Taiwan 
 
N=91 
 
n=48 
intervention 
group of 
saline mouth 
rinse 
regimen with 
education 
program  
 
n=42 
provided with 
standard of 
care 
To test the 
effectiveness 
of a saline 
mouth rinse 
regimen and 
educational 
program on 
OM and 
quality of life 
in patients 
with oral 
cavity cancer 
post 
operation but 
before 
induction of 
treatment  
Radiation-
induced OM 
evaluated 
WHO Oral 
Toxicity 
Scale 
 
7-item MSS-
moo, an 
instrument that 
assesses 
radiation-
induced 
OM-related 
symptoms 
 
UW-QOL; 
measures 12 
domains of 
health: pain, 
appearance, 
activity, 
recreation, 
No 
statistically 
significant 
findings in 
improvement 
in radiation-
induced OM 
symptoms 
and overall 
QOL was 
find between 
the two 
groups; 
 
Physical 
function QOL 
significantly 
improved 
from pre-test 
to post-test 
(Fw = 3.468, 
p < .01) 
 
Limited to 
oral cancer 
patients  
 
Interventio
n excluded 
patients 
with mild-
to-
moderate, 
radiation 
induced 
OM 
 
Patients 
who 
appeared 
to be in 
pain during 
recruitment 
were 
excluded.   
Saline mouth 
rinses along 
with an 
educational 
program are 
effective 
interventions 
in increasing 
physician and 
social-
emotional 
quality of life 
by improving 
the symptoms 
of OM when 
compared to 
standard of 
care.   
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swallowing, 
chewing, 
speech, 
shoulder, 
taste, saliva, 
mood and 
anxiety with 2 
global items 
reflecting 
health-related 
and overall 
QOL 
 
Baseline data 
collected 
across both 
groups, first 
postoperative 
clinical visit, 
and post-test 
at 8 weeks. 
 
ANOVA test 
A statistically 
significant 
group × time 
interaction 
(Fin = 4.627, 
p < .05) 
indicated that 
social-
emotional 
QOL in the 
experimental 
group 
(70.22–
78.11) 
improved 
more 
significantly 
than in the 
control group 
(69.37– 
69.96) after 8 
weeks. 
Lee, S. (2015). 
Mineral derivatives in 
alleviating oral 
mucositis during 
cancer therapy: A 
systematic 
review. Peerj,3e:765. 
doi:10.7717/peerj.76
5 
 
Level I, Grade A 
Systematic 
review of 
RCTs with 
meta-
analysis  
16 studies 
included, 
n=1120  
The effects 
of using 
mineral 
derivatives in 
treating OM 
when 
compared to 
the standard 
of care or 
placebo in 
any cancer 
types, 
population of 
Binary and 
continuous 
data 
synthesized  
Hedges’ g in a 
random effects 
model 
 
Decision tree 
mapped 
sensitivity, 
specificity, pre-
test and post-
Mineral 
derivatives 
were less 
likely to 
experience 
peak 
OM than 
those without 
treatment (g 
= −0.47, 95% 
CI −0.7 to 
−0.2, p = 
0.0006, I2 = 
No clear 
recommen
dations can 
be made 
based on 
the study 
 
Unable to 
make 
clinical 
practice 
recommen
dations  
The meta-
analysis 
suggests 
mineral-
derivatives 
have a 
positive effect 
in reducing 
severity of 
OM for patient 
receiving 
cancer 
treatments 
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all ages, 
undoing 
various 
cancer 
treatments  
test Baybesian 
probability  
  
61%). 
 
Treatment 
groups (n = 
958) 
experienced 
peak 
OM less than 
controls (g = 
−0.47,95% 
CI −0.7 to 
−0.2, p = 
0.0006) 
 
OM onset 
was 
significantly 
delayed in 
treatment 
than controls 
(g = −0.51, 
95% CI−0.8 
to −0.2, p = 
0.0002; 
 
 
 
 
Supports 
positive 
effects for 
Zinc sulfate in 
prevention 
and treatment 
of oral 
mucositis  
 
 
 
 
McGuire, D. B., 
Fulton, J. S., Park, J., 
Brown, C. G., Correa, 
M. E. P., Eilers, J., ... 
& Lalla, R. V. (2013). 
Systematic review of 
basic oral care for the 
management of oral 
mucositis in cancer 
patients. Supportive 
Care in 
Systematic 
Review  
52 studies 
that included 
only primary 
research with 
a verity of 
designs 
To evaluate 
research of 
oral care 
interventions 
and update 
EBP 
guidelines for 
preventing 
and treating 
OM 
OVID/MEDLIN
E databases 
searched; 
search terms 
of mucositis, 
stomatitis, 
cancer, oral 
care, oral care 
protocol, 
dental care, 
n=24 studies 
tested oral 
protocols 
found 
positive 
effects 
across 
various 
populations 
including 
children 
Lack of 
evidenced 
for 7 
interventio
ns  
 
Guidelines 
unable to 
be 
developed 
Use of oral 
care protocols 
in prevention 
of OM in all 
age groups 
and treatment 
modalities 
 
Chlorhexidine 
should not be 
used to 
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Cancer, 21(11), 
3165-3177. 
 
Level III, Grade A 
 
dental 
cleaning, oral 
decontaminatio
n, oral 
hygiene, 
saline, 
sodium 
bicarbonate, 
baking soda, 
chlorhexidine, 
magic/ 
miracle 
mouthwash, 
and calcium 
phosphate 
 
Articles from 
1950 to 2010 
 
52 studies met 
inclusion 
criteria  
 
No 
recommenda
tions for 
dental care, 
normal saline 
mouthwash, 
sodium 
bicarbonate 
mouthwash, 
chlorhexidine 
mouthwash, 
mixed 
medication 
mouthwash, 
and calcium 
phosphate 
mouthwash.   
 
Guidelines 
suggest 
against using 
chlorhexidine 
mouthwash 
in head and 
neck cancers  
based on 
data  
prevent OM in 
head and 
neck cancer 
patients  
 
Normal saline 
and sodium 
bicarbonate 
mouth rinses 
are viewed as 
harmless 
when 
included in 
routine oral 
care practices 
 
 
Moslemi, D., Babaee, 
N., Damavandi, M., 
Pourghasem, M., & 
Moghadamnia, A. A. 
(2014). Oral zinc 
sulphate and 
prevention of 
radiation-induced 
oropharyngealmucosi
tis in patients with 
RCT Babol 
University of 
Medical 
Sciences in 
the 
Department 
of 
Radiotherapy 
 
N=40 
To research 
the potential 
benefits of 
zinc sulphate 
in the 
prevention of 
radiation 
induced OM 
in head and 
neck cancers  
The Mann ‐
Whitney, 
Fisher’s exact, 
Pearson chi‐
square tests 
and Friedman 
variation 
analysis,  
Weeks 2-8, 
the severity 
of oral and 
pharyngeal 
mucositis 
were lower in 
the zinc 
group, 
(p<0.003) 
Specific 
cancer 
type; 
limited to 
head and 
neck 
 
Small 
sample 
size 
Zinc sulphate 
(30 mg, TID) 
can reduce 
oropharyngea
l mucositis, 
delays 
initiation of 
mucositis 
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head and neck 
cancers: A double 
blind, randomized 
controlled clinical 
trial. International 
Journal of Radiation 
Research, 12(3), 
235-241. 
 
Level I, Grade B 
 
 
Randomly 
divided n=20 
experimental 
group, n=20 
placebo 
group 
 
 
Slade, S. (2017). 
Oral mucositis: 
Treatment [Evidence 
Summaries]. 
Retrieved from 
Joanna Briggs 
Institute database. 
(Accession No. 
JBI15068) 
 
Level V, Grade A 
Evidence 
summary  
Incorporated 
data from 8 
systematic 
reviews, 2 
Cochrane 
systematic 
reviews, 1 
Evidenced-
based 
clinical 
guideline, 7 
RCTs, 1 
controlled 
trail, and 
Included 
articles 
based on 
expert 
opinion, non-
analytic 
studies, and 
relevant 
literature 
Determine 
best practice 
guidelines for 
prevention of 
oral 
mucositis in 
patients 
receiving 
cancer 
treatments  
RCT that 
included 24 
participants 
 
RCT that 
included 225 
participants 
 
5 RCTs 
 
Cochrane 
systematic 
review that 
included 131 
studies and 
10,514 
participants 
 
Cochrane 
systematic 
review that 
included 35 
RCTs with a 
Range of 
interventions 
found to be 
useful but 
advised 
benefits may 
apply to 
specific 
cancers/treat
ments 
 
Cryotherapy, 
Keratinocyte 
Growth 
Factor, in 
some 
cancer/treat
ment types 
are effective 
at reducing 
OM 
 
Low-lever 
laser therapy 
Best 
practice 
recommen
dations are 
limited to 
some 
exclusive 
cancer or 
treatment 
types 
 
There is 
potential 
bias or lack 
of 
generaliza
bility in the 
studies 
used.  
Preventative 
oral care 
regimens 
should be in 
place 
 
Oral pain 
should be 
self-reported 
using a 
validated tool 
on a regular 
basis  
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total of 3,102 
participants 
Systematic 
review of 27 
studies 
 
Systematic 
review of 52 
published 
papers 
 
Systematic 
review 49 
papers across 
15 
interventions 
 
Systemic 
review of 54 
oral 
assessment 
instruments 
 
Systematic 
review of 24 
trials 
 
Systematic 
review that 
included 64 
clinical studies 
 
Systematic 
review of 22 
clinical studies 
is a good 
alternative 
for 
prevention of 
OM 
 
Regular 
assessment 
of patient-
reported oral 
pain using a 
validated tool 
is 
recommende
d 
 
Preventive 
oral care 
should be in 
place 
 
Before 
starting 
cancer 
treatment, 
dental 
examinations 
and 
treatment 
should be 
carried out 
 
Chlorhexidin
e mouthwash 
and 
glutamine 
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and 2 meta-
analyses 
 
Articles based 
on expert 
opinion, non-
analytic 
studies and 
relevant 
literature.  
 
 
preparations 
are not 
recommende
d for head 
and neck 
cancer 
patients 
Obeid, S. (2018). 
Oral mucositis: 
Assessment 
[Evidence 
Summaries]. 
Retrieved from 
Joanna Briggs 
Institute database. 
(Accession No. 
JBI15067) 
 
Level V, Grade C 
Evidence 
summary 
2 systematic 
reviews  
 
1 
observational 
study  
Determine 
best practice 
guidelines 
regarding the 
assessments 
of oral 
mucositis in 
patients  
Systematic 
review of oral 
assessment 
instruments for 
children and 
young people 
including 53 
studies 
 
Observational 
study with 33 
participants 
 
Systematic 
review 
including 104 
studies and 
evidenced-
based 
recommendati
on 
Healthcare 
professionals 
should 
educate 
people with 
cancer about 
OM 
 
Standardized 
oral 
assessment 
for all 
patients 
should occur 
using a 
validated tool 
prior to 
assessment 
and 
throughout 
treatment. 
 
Oral 
assessment 
There is 
potential 
bias or lack 
of 
generaliza
bility in the 
studies 
used. 
Healthcare 
professionals 
need to 
discuss, 
inform, and 
educate 
patients about 
OM and its 
assessment 
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tool should 
have patient 
subjective 
experiences 
in order to 
address 
patient 
experience 
 
Patient 
reported 
assessment 
tools may 
complement 
clinician-
determined 
measures or 
as stand-
alone 
assessments 
when 
addressing 
OM 
 
OM 
assessment 
tools by 
clinicians 
should be 
standardized 
across all 
patients 
within a 
health 
service 
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User should 
be trained in 
correct 
manner to 
use 
assessment 
tool.  
 
 
Yarom, N., 
Ariyawardana, A., 
Hovan, A., Barasch, 
A., Jarvis, V., 
Jensen, S. B., . . . 
Mucositis Study 
Group of the 
Multinational 
Association of 
Supportive Care in 
Cancer/International 
Society of Oral 
Oncology 
(MASCC/ISOO). 
(2013). Systematic 
review of natural 
agents for the 
management of oral 
mucositis in cancer 
patients. Supportive 
Care in Cancer, 
21(11), 3209-3221. 
doi:10.1007/s00520-
013-1869-5 
 
Level II, Grade A 
 
Systematic 
Review  
49 papers, 
various types 
of studies  
To 
systematicall
y review 
current 
literature and 
construct 
clinical 
practice 
guidelines for 
use of 
natural 
agents in the 
prevention 
and 
treatment of 
OM 
OVID/MEDLIN
E databases 
searched; 
search terms 
alternative, 
complementar
y, 
homeopathic, 
aloe vera, 
beta-carotene, 
chamomile, 
chinese herbal, 
folic acid, 
glutamine, 
hydrolytic 
enzyme, MF 
5232 
(mucotrol), 
multivitamin, 
natural, 
polaprezinc, 
traumeel, 
tretinoin, 
vitamin, zinc, 
honey, 
manuka & 
kanuka oil, 
Glutamine is 
not 
recommende
d by IV for 
prevention of 
OM, no 
guidelines 
possible for 
other modes 
of intake  
 
No 
guidelines 
possible for 
various 
vitamin or 
combination 
of vitamin 
and 
supplements 
 
No guideline 
possible for 
honey 
 
Oral 
systematic 
Guidelines 
unable to 
be 
developed 
for several 
interventio
ns based 
on data 
 
Recommen
ded 
guideline 
limited to 
one cancer 
type.  
IV Glutamine 
is not 
recommende
d for 
prevention of 
OM in 
patients 
receiving 
cancer 
treatments 
 
Systemic zinc 
supplements 
may help 
prevent OM in 
oral cancer 
patients 
receiving 
oncological 
treatments  
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Rhodiola 
algida, vitamin 
A, vitamin E, 
Wobe-Mugos 
E, retinoid, and 
indigo wood 
root. 
zinc 
supplements 
maybe of 
benefit in 
preventing 
OM in 
oncological 
treatments 
 
No guideline 
for aloe vera 
gel, 
chamomile 
mouthwash, 
or Chinese 
herbal drug 
mouthwash.  
 
No 
guidelines for 
indigowood 
root  
 
No 
guidelines for 
manuka and 
kanuka oils, 
Mucotrol, R. 
algida, 
Traumeel S, 
Wobe-mugo 
E/proteolytic 
enzymes 
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Organization Oral Toxicity Scale, interobserver reliability of 0.99, and MacDibbs Symptom Score 
– Modified for oral cavity care and University of Washington Quality of Life scale, both having 
Cronbach’s scores higher than 0.90.  Differences in the quality of life (QOL) indices for physical 
function and socio-emotional function were statistically significant between groups. Significant 
findings were noted the physical functioning quality of life scores when compared to interactions 
between groups and within the pre and post-test (Fin = 4.114, p < 0.05)- The social-emotional 
function of QOL in the experimental group improved more significantly than in the control group 
(Fin = 4.627, p < 0.05) after eight weeks. However, this study did not find improvement in OM 
symptoms overall. This may have been the result of delayed recruitment into the study, which 
occurred in week 5 of treatment.  Limitations of the study included the restriction of eligibility to 
only those patients with clinically severe OM and the lack of assessment of family social support 
and nutritional status of patients.  Despite these limitations, this study supports that saline 
mouth rinses with an educational program increases the physical and social-emotional quality of 
life in patients with OM (Huang et al., 2018).  This RTC receive a quality rating of B due to 
results that were classifiable as reasonably consistent.   
Carvalho, Medeiros-Filho, & Ferreira (2018) performed a systematic review without 
meta-analysis in efforts to evaluate the available evidence and draft a guide for medical 
professionals that involved oral care for oncological patients.  Criteria for studies included only 
systematic reviews of RCTs and individual RCTs. Extensive database searches occurred 
across the Cochrane Library, MEDLINE/PubMed and EBSCOHost databases.  Inclusion and 
exclusion criteria are clearly defined. A flow diagram is provided that provides detailed 
information on how studies were eliminated at each level of review.  Methodological quality was 
determined based on the “Assessing the Methodological Quality of Systematic Review” 
(AMSTAR) and “Method for Evaluating Research and Guideline Evidence” (MERGE) by two 
independent researchers. Conclusions were discussed for the interpretation and systematic 
data review.  Authors recommended that, prior to oncological treatments, oral hygiene best 
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practices should be taught, including the recommendation of brushing 3x daily with ultra-soft 
toothbrushes, fluoride toothpaste and dental floss. In the event of xerostomia education should 
include the practices of lubrication and hydration of the oral mucosa.  Ongoing assessments 
should be done before, during, and after oncological treatments.  Recommendations also 
include that a professional oral examination should be performed prior to initiation of oncological 
treatments.  This study strongly supports that a preventive oral care program should be followed 
to reduce complications (Carvalho, Medeiros-Filho, & Ferreira, 2018).  Quality rating for this 
article is a B because results lack generalizability across populations and analytical data is not 
present.   
 Level II Evidence. A systematic review conducted by Yarom et al., (2013) addressed 
the use of natural agents for the management of OM in patients receiving oncological 
treatments.  A comprehensive database search was conducted and inclusive key terms relative 
to the topic were provided. The resulting evidence was reviewed by two independent reviewers 
and evaluated based on a list of major and minor flaws.  The Somerfield criteria were used to 
assign the appropriate level of evidence.  Systematic review did not include a flow diagram but 
did provide narrative on the inclusion and exclusion process.  Yarom et al., (2013) included in 
the review 49 papers across 15 interventions in the systematic review.  Conclusions flowed 
logically and based on the scientific data presented. However, one limitation noted in the studies 
included that the systematic review focused chiefly on head and neck cancers and not cancers 
in general. Two recommendations developed from the systematic review in reference to 
preventing OM: one against the use of glutamine and one supporting the use of zinc sulfate in 
head and neck cancer patients (Yarom et al., 2013). This evidence supports the use of zinc 
sulfate as a preventative in patients receiving oncological therapies in the treatment of head and 
neck cancers. The quality rating assigned to this study is A because it meets the standards of 
transparency, diligence, verification, and low risk of bias due to the use of an independent 
researchers screening data before inclusion.    
ORAL MUCOSITITS PREVENTION   45 
 
 
Cidon (2018) conducted a prospective cohort study to examine if a specialty mouthwash 
that was composed of 100 milliliters of water, 5 milligrams of soluble prednisolone, 2 drops of 
nystatin and 2.3 mg of salt.  The combination was suggested to help prevent reoccurrence of 
OM in breast cancer patients who had developed OM during previous chemotherapy cycles. It is 
noted that before the study, all patients had been educated to continue an oral hygiene protocol 
and were in good dental health.  A total of 68 patients were included in the study; all women 
undergoing treatment for breast cancer with various oncological therapies.  Other demographics 
are not provided and the research took place at a single institution in Bournemouth, UK. Data 
was obtained by professional visual assessment using the World Health Organizational (WHO) 
grading criteria for OM and a seven-question patient survey. Instrument validity was not 
discussed and was without Cronbach’s alpha data. Findings were statistically significant based 
on binomial testing indicating the probability of grade 2 to 3 OM after using this mouthwash was 
lower (2.9% p < 0.0001) and the likelihood of grade 2 OM was significantly less severe in those 
that used the special mouthwash  (11.7%, p < 0.0001). The main limitation of this study was the 
small sample size which may have been inadequate to detect a truly significant difference. 
Additionally, since all participants were females with breast cancer, findings may not be 
generalizable to men with breast cancer or patients of any gender with non-breast cancer. The 
authors did not describe the evidence they used to support rational of the choice of ingredients 
included in the mouthwash formulation, so the empirical underpinnings of their intervention are 
unclear.  Finally, patients were noted to have previously had OM and had received oral care 
education, which is an independent variable that needed to be explored. This study provides 
weak, though statistically compelling, evidence to support mouthwash as a care strategy for 
prevention or reduction of OM and receives a quality rating of C due to the methodological flaws 
outlined above.   
Level III Evidence. Cullen and colleagues (2018) conducted a descriptive study to 
evaluate the use of oral care kits and oral care education for patients receiving radiation therapy 
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for head and neck cancers at a large academic medical center. The study took place at an 
accredited comprehensive cancer center. Patients were divided into two groups by opportunity 
sampling, with the first 20 patients receiving the standard of care and the next 85 patients 
serving as the experimental group. Both groups were treated similarly with the comparison 
group receiving standard care, which included extensive oral care preparation: Oncologic 
dentist evaluation, fluoride treatments, provisions of oral care supplies, and tooth extraction 
when necessary. The intervention group received standard care plus an oral care kit and 
extensive instructions on how to use it.  Data were collected at the same treatment points in 
both groups, with surveys being used for data collection.  Cronbach’s alpha and instrument 
validity were not discussed. Data to assess clinician knowledge was collected pre- and post-
intervention by using a pre and post-test method. Correct response to knowledge assessment 
increased from 71% to 80% postimplementation (n=20/29).  Patient data was collected pre-
oncological treatment, at week 4-5 of treatment, and one month after treatment ended.  Patients 
in the intervention group reported less severity than usual care patients in various symptoms: 
Mouth and throat soreness (3.9 versus 5), difficulty swallowing (4 versus 5.6), difficulty eating (4 
versus 5.9), difficulty talking (2.9 versus 4), and less difficulty with xerostomia (3.1 versus 4.1) 
(Cullen et al., 2018).  This study supports the use of evidence-based oral care, oral care kits, 
and educational materials on judicious oral care.  The study is considered A on the quality 
rating, due to transparency, diligence, verification, self and instructional reflection, and 
participant-centered inquiry.   
McGuire and colleagues (2013) conducted a systematic review without meta-analysis 
evaluating research focused on basic oral care interventions in efforts to update EBP guidelines 
for preventing and treating OM.  OVID/MEDLINE database was searched using a 
comprehensive list of keywords.  Accepted article types were research studies of various 
designs. Stringent inclusion and exclusion criteria were used to discover best evidence for the 
prevention or treatment of OM. A structured clinical review was conducted for each article, with 
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analysis using the Hadorn criteria for assessing flaws and the Somerfield schema for rating level 
of evidence.   Included in the review were 52 studies across seven interventions; (a) oral care 
protocols, (b) dental care, (c) normal saline, (d) sodium bicarbonate, (e) chlorhexidine, (f) mixed 
medication mouthwash, and (g) calcium phosphate.  Researchers concluded that oral care 
protocols in the prevention of OM in all age groups and across all cancer treatments are 
recommended. No recommendations could be made for normal saline or sodium bicarbonate 
mouthwashes; however, research supported bland rinses can be helpful for both patient comfort 
and oral hygiene maintenance by an expert panel (McGuire et al., 2013).  Evidence supported 
the use of an oral care protocol as a method of preventing OM.  Evidence provided met the 
criteria of A quality for a systematic review.  
Level V Evidence. Ferrington, Cullen, & Dawson (2013) implemented EBP 
recommendations for the prevention and treatment of OM across a diverse population.  
Recommendations were based on a synthesis of the evidence, providing consistent results from 
different sources about oral care in patients receiving oncological treatment. Literature included 
in the synthesis was timely and relevant to the topic.  Meaningful conclusions drawn from the 
information were presented. A web-based evaluation tool was distributed to nursing staff 
(n=117) three months after EBP oral care protocol was implemented to identify areas that 
needed additional education.  Researchers found that nurses were knowledgeable in: (a) use of 
soft toothbrushes – 100%, (b) Biotene toothpaste – 97%, however, reinfusion was required for 
topics of (c) Assessment – 55%, (d) flossing knowledge – 56%, (e) correct lip care -46% and (f) 
correct rinses for OM.  This quality improvement initiative supports frequent oral hygiene for 
populations at risk for OM and the implementation of an EBP policy for oral care as a preventive 
measure against OM (Ferrington, Cullen, & Dawson, 2013).  The organization experience 
presented in review meets the quality rating of A, related to clear aims and objectives, formal 
improvement plan, evaluation methods and being based on scientific evidence.   
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Researchers da Cruz Campos, Campos, Aarestrup, & Aarestrup (2014) performed a 
literature review to critically evaluate OM, its causes, and treatments in efforts reduce patient 
suffering.  The researchers provided meaningful data on known causes, risks, and contributors 
to OM in their review.  Additionally, researchers presented evidence that supports the concept 
that professional oral care should be provided before oncological treatments and recommended 
treatments for OM.  The literature review is aimed at dental professionals, but it includes 
supportive information applicable to nursing.  Gaps are not fully explored, however, there is 
acknowledgment that further research is required.  Recommendations supported by this review 
include instructing patients on oral hygiene and professional dental care prior to initiation of 
chemotherapy or radiotherapy (da Cruz Campos, Campos, Aarestrup, & Aarestrup, 2014).  For 
this literature review, the researcher’s expertise appears to be credible and reasonably definitive 
conclusions are drawn, meeting the quality ratings of B.  
Eilers, Harris, Henry, & Johnson, (2014) conducted a systematic review, but due to the 
inclusion of expert opinions and other nonresearched evidence, it is addressed as a literature 
review under Appendix D of ©The Johns Hopkins Hospital/The John Hopkins University nursing 
EBP guide (Dang & Dearholt, 2017).  Researchers searched PubMed and CINAHL databases, 
and after inclusion and exclusion criteria were addressed, 104 articles were included for review. 
This research was attached to a body of knowledge that appeared in a previous publication.  
Based on the literature reviewed, five recommendations for practice were made: (a) 
cryotherapy, (b) low-level laser therapy, (c) oral care protocols, (d) palifermin, and (e) sodium 
bicarbonate mouth rinses.  Other interventions were categorized as likely to be effective or 
effectiveness not established.  Gaps in research were discussed, and recommendations for 
practice were noted by the researchers (Eilers, Harris, Henry, & Johnson, 2014). This article 
met the criteria for a quality rating of A.  
 Slade (2017) developed an evidence summary that identified the best evidence 
regarding OM prevention for patients with cancer.  Evidence was developed from Cochrane 
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systematic reviews with one that included 131 studies and 10,514 participants and another 
included 35 RCTs with a total of 3,102 participants, systematic review including 27 studies, 
systematic review of 52 published papers, systematic review 49 papers across 15 interventions, 
systematic review of 54 oral assessment instruments, systematic review of 24 trials, systematic 
review that included 64 clinical studies, systematic review of 22 clinical studies and 2 meta-
analyses, and an unspecified amount of articles based on expert opinion, non-analytic studies 
and relevant literature.  Analytical evidence was not provided in the summery, instead data 
points were assigned a grade of A or B for the strength of the recommendations. Best practice 
recommendations were:  
[a] The use of cryotherapy (ice chips) and Keratinocyte Growth Factor appear to be 
effective in preventing mucositis (Grade A). [b] The ease of use of low-level laser 
therapy, high patient acceptance, and the positive results achieved, suggest this therapy 
is a good alternative for the prevention of oral mucositis for people undergoing 
chemotherapy and radiotherapy (Grade B). [c] Regular assessment of oral pain using a 
validated tool that uses self-reporting is recommended (Grade B). [d] Preventative oral 
care regimens should be in place, with therapeutic oral care regimens in place if 
mucositis develops (Grade B). [e] Prior to beginning cancer therapy, dental examinations 
and treatment should be carried out, and continued during treatment (Grade B). [f] 
Chlorhexidine mouthwash and glutamine preparations are not recommended for patients 
undergoing treatment for head and neck cancer. (Grade A) (Slade, 2017, p 3). 
The study did not include search, inclusion or exclusion materials, or gaps in literature. 
However, there are reasonably consistent findings, inclusion of well-designed studies, and 
definitive conclusions drawn, allowing the quality rating of B.   
 Obeid (2018) developed an evidence summary addressing the best evidence regarding 
the assessment of OM in patients with cancer receiving oncological treatments.  Research 
included in developing the best practice recommendations included a systematic review of oral 
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assessment instruments for children and young people including 53 studies, observational study 
with 33 participants, and a systematic review including 104 studies.  Analytical evidence was not 
provided but assigned a grade of A or B was provided for the strength of the recommendations. 
Best practice recommendations were:  
[a] Healthcare professionals should ensure that they discuss and educate each person 
with cancer about oral mucositis and its assessment. (Grade A). [b] Standardized oral 
assessments for all patients using an appropriate, validated tool should occur prior to 
treatment and then regularly throughout treatment (Grade A). [c] Oral assessments 
should include a separate measurement of pain and other symptoms to assess the 
patients’ experience (Grade A). [d] Patient-reported assessment tools may be useful to 
both complement clinician-determined measures of oral mucositis or as standalone 
assessments when patients cannot undergo clinician-assessed assessments (Grade A). 
[e] The use of oral mucositis assessment tools by clinicians should be standardized 
across all patients within a health service(Grade A). [f] Users should be trained in the 
consistent and correct use of the chosen assessment tool (Grade A). (Obeid, 2018, p. 2) 
The study did not include search, inclusion or exclusion materials, or gaps in literature. Though 
definitive conclusions are drawn, information was drawn from a relativity small pool of data, 
raising questions of whether recommendations are fully discernable. Due to this flaw, it was 
assigned a quality rating of C.   
Construction of Evidence-based Practice 
 The foundation for EBP is the judicious examination and appraisal of the best available 
evidence.  To develop this EBP project, synthesis of the evidence is required to allow the 
formation of best practice recommendations regarding OM prevention in patients receiving 
oncological treatments.  The synthesis of the literature and best practice recommendations are 
examined in detail.   
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 Synthesis of critically appraised literature.  An in-depth appraisal of current and 
relevant literature exploring the best way to prevent OM in patients receiving oncological 
treatment allowed an intimate understanding of EBP measures.  Evaluation of the literature 
produced evidenced-based themes and strategies to address the prevention of OM.   
 The appraisal of the literature revealed four objectives in the prevention of OM.  These 
objectives included (a) having an oral care protocol in place, (b) use of subjective assessment 
tools, (c) professional clinical knowledge of OM, and (d) zinc sulfate as a preventive.  
Overwhelmingly, the need for structured oral care routine was noted throughout the literature, 
with seven studies referencing the importance of this measure (Carvalho et al., 2018; Cullen et 
al., 2018; da Cruz Campos et al., 2014; Eilers et al., 2014; Farrington et al., 2013, Huang et al., 
2018; McGuire et al., 2013 & Slade, 2017).  Tools to monitor and assess for complications of 
OM were noted as important themes in five studies (Carvalho et al., 2018; Cullen et al., 2018, 
Eilers et al., 2014; Slade, 2018 & Obeid, 2018).  Five studies referenced the need for 
professional knowledge about OM in both reference to skillful assessment and divulging 
knowledge to patients (Cullen et al., 2018, da Cruz Campos et al., 2014; Eilers et al., 2014, 
Farrington et al., 2013 & Obeid, 2018).  Three studies examining OM prevention concluded that 
zinc sulfate was effective as preventive measure (Lee, 2015; Moslemi et al., 2014 & Yarom et 
al., 2013).  
 An important prevention step, found in seven of the studies, was that structured oral care 
protocols should be in place before a patient starts oncological treatments.  Four of the studies 
addressed the need for formalized oral care protocols to be in place prior to starting treatment 
(Eilers et al., 2014; Farrington et al., 2013, Huang et al., 2018 & McGuire et al., 2013).  The 
other three studies addressed the need for education regarding routine or therapeutic oral care 
measures (Carvalho et al., 2018; Cullen et al., 2018 & Slade, 2017).   
Examination of necessary components of structured oral care occurred. Four of the 
studies address mouth rinse (Cidon et al., 2018, Eilers et al., 2014, Huang et al., 2018 & 
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McGuire et al., 2013).  Three of the studies (Cullen et al., 2018, Eilers et al., 2014; & Farrington 
et al., 2013) endorse a rinse of salt and baking soda, also called sodium bicarbonate. One study 
also notes salt water (Farrington et al., 2013) can be used.  In one study, normal saline and 
sodium bicarbonate solutions were viewed as harmless when part of an oral care practice and 
may promote patient comfort (McGuire et. al., 2013).  Oral cavity care, including lip care, tooth 
brushing, flossing (unless at high risk for bleeding), and oral rinses, were addressed in three 
studies (Cullen et al., 2018, Eilers et al., 2014; & Farrington et al., 2013).  Two studies specified 
that the toothpaste used in oral care interventions needs to be both non-abrasive (Cullen et al., 
2018) and free of pyrophosphates and sodium lauryl sulfate (SLS) (Farrington et al., 2013).   
The next evidence-based strategy produced from analysis of the literature was the 
necessity of using a consistent assessment tool. Seven studies provided evidence that that an 
oral assessment tool should be used throughout treatment (Carvalho et al., 2018; Cidon, 2018; 
Cullen et al., 2018; Eilers et al., 2014, Huang et al., 2017; Obeid, 2018 & Slade, 2017).  
Suggestions for the types of tools that should be used to evaluate OM, three studies suggested 
use of a patient reported tool (Cullen et al., 2018; Obeid, 2018 & Slade, 2017) while the other 
two did not specify (Carvalho et al., 2018 & Eilers et al., 2014).  Two experimental studies 
(Cidon, 2018 & Huang et al., 2017) used a combination of both subjective and objective 
assessment tools for collection of data.   
The next EBP concept that emerged was importance of professional knowledge 
concerning teaching about and assessing OM.  There was a total of five studies acknowledging 
the importance of the professionals’ knowledge (Cullen et al., 2018, da Cruz Campos et al., 
2014; Eilers et al., 2014, Farrington et al., 2013 & Obeid, 2018).  In the study by da Cruz 
Campos et al., (2014) it was noted that a clinical dentist should instruct patients on oral hygiene 
methods.  Two studies use it as an implementation measure and evaluation of nursing 
knowledge (Cullen et al., 2018 & Farrington et al., 2013). Two studies addressed it as an 
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indication for practice when working with patients who are at risk for developing OM (Eilers et 
al., 2014 & Obaid, 2014).   
In efforts to prevent OM in patients undergoing oncological therapies, zinc sulfate was 
found to be beneficial in three studies (Lee, 2015; Moslemi et al., 2014 & Yarom et al., 2013).  A 
meta-analysis of high quality RTCs found that mineral derivatives, especially zinc sulfate, were 
helpful in the treatment and prevention of OM (Lee, 2015).  In a double-blind, randomized RTC, 
Moslemi (2014) found that zinc sulfate reduces OM and delays its onset of 
oropharyngealmucositis in head and neck cancers. In a systematic review addressed by Yarom 
et al., (2013), evidence supported the use of zinc sulfate, but recommendation was limited to 
oral cancers.   
Best practice model recommendation.  The EBP recommendations were developed 
from synthesis of the best available evidence.  Oncological therapies are linked to the 
development of OM which can lead to diminished patient outcomes. This condition is one of the 
most severe non-hematological complication that occurs during oncological treatments (da Cruz 
Campos et al., 2014).  Having preventive measures in place can lead to better patient 
outcomes.  Therefore, due to evidence-based recommendations, an oral care protocol was 
developed as the standard of care for all patients in an outpatient facility that provided 
oncological treatments. Clinical team members were educated on the oral care protocol, use of 
a validated patient-reported tool, and key points of educational handouts provided to patients.  
Once the oral care protocol was in place and all patients were receiving the standard of care, 
zinc sulfate supplementation was introduced to patients under a select provider.  
How the best practice model will answer the clinical question.  The best available 
evidence concludes that having an oral care protocol in place, assessing patients through their 
oncological treatments with a valid tool, having clinicians knowledgeable in OM and OM 
prevention measures, and zinc sulfate supplementations are all evidence based measures to 
prevent OM.  Utilization of preventive measures will lead to better outcomes for patients by 
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reducing the risk that OM poses to their health while they are receiving oncological treatments.  
The incorporation of an oral care protocol that includes zinc supplementation as suggested by 
evidenced-based recommendations was used to answer the clinical question: “In patients 
receiving oncological treatments, does an oral care protocol with zinc sulfate supplementation 
reduce complications related to oral mucositis at greater rates than an oral care protocol alone, 
as measured by a patient reported assessment tool over a six week period?”  
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CHAPTER 3 
IMPLEMENTATION OF PRACTICE CHANGE  
 The evidence presented in Chapter 2 supports the development of an oral care protocol 
as the standard of care along with additional zinc supplementation to prevent oral mucositis in 
cancer patients receiving oncological treatments.  This chapter will describe the setting, 
participants, outcomes, intervention, data management, and analysis plan.  Also included are 
the steps to protect human subjects.  This EBP project serves to address to address the 
following PICOT question: “In patients receiving chemotherapy treatments, does an oral care 
protocol with zinc sulfate supplementation, compared to the standard of care (oral protocol 
alone), reduce complications related to oral mucositis as measured by a patient-reported 
assessment tool over a six-week period?”  
Participants and setting 
 This EBP project occurred at an outpatient infusion center that provided oncology and 
hematology services.  The group of providers at this office consists of four physicians who are 
experienced in medical oncology, hematology, and internal medicine and all have achieved 
board certification for these specialties. The daily staff is typically two or more physicians who 
rotate schedules between the two offices, a nurse practitioner, two oncology-certified nurses, 
three medical assistants, and a care technician.  The office infuses between 30 and 50 
oncological agents on an average day.  The average patient age is 58.  The most common type 
of cancer patients receive treatment for is lung cancer. Each physician has their patient care 
loads to which they do office visits, review labs, develop chemotherapy care plans and other 
tasks.  The nurse practitioner reviews labs and adjusts chemotherapy plans as needed based 
on lab results and performs other administrative duties. The two oncology-certified nurses mix 
and administer oncological or hematological treatments. The medical assistants perform lab 
draws, monitor pumps, start peripheral intravenous access, run lab equipment, and deliver labs 
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to the correct personnel for review.  The care technician sits in a central area surrounded by 
bays, monitoring individuals during treatments and responding to patient bells.   
The office accepts most commercial and managed care insurance plans, including 
Medicare and Medicaid.  Also, they have an onsite financial staff to assist patients through 
various billing arrangements.  This office serves an area where the average median household 
income is less than the annual average wage in the United States (United States Census 
Bureau, 2016).  The overall poverty rate for the community was over 16% which is above the 
national average of 14.7% (United States Census Bureau, 2016). When an individual cannot 
afford treatment, the office will apply for assistance from the pharmaceutical companies, obtain 
samples until insurance coverage can start, or in emergent cases, admit to the hospital to 
initiate treatment.   
Participants eligible for this evidence-based practice project were ones who presented to 
the infusion center for their initial dose of chemotherapy and were willing to participate in the 
study.  Participates were required to be fluent in English and mentally competent to fill out the 
survey tool independently.  Patients groups underwent chemotherapy infusions that were 
customized to treat their specific cancers and managed by the oncologist and coordinating care 
team.   
Design 
 The project used a two-group pretest-posttest quasi-experimental design.  Participants 
were assigned to groups based on the oncologist that was managing their care at the time of 
the project.  One provider provided their patients with zinc sulfate as part of the treatment plan 
with education that the supplement was being used to prevent OM during their course of 
treatment.  The other providers, who did not provide zinc supplementation to their patient load, 
served as the comparison group. All participants were followed for six weeks through the course 
of their treatments, despite overall treatment length.  All received the standard of care, which 
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was the oral care protocol with education to continue stringent oral care until the end of their 
chemotherapy regimen.   
Outcome 
The primary outcome for this project was to assess for the reduced incidence and 
severity of OM in patients receiving zinc compared to the standard of care alone. Oral mucositis 
is an adverse effect that often occurs in patients undergoing treatment for cancer. This condition 
is known to have negative impacts on nutrition, oral hygiene, quality of life, and can lead to 
significant weight loss, pain, dehydration, or life-threatening infections (Slade, 2017 & Yarom et 
al., 2013).  Prevention and reduction of OM have been studied primarily in head and neck 
cancers. However, no studies found explored the reduction of OM in patients receiving 
oncological treatments for various cancer types. With incidence rates ranging from 40% to 
100% and the increased complications related to OM, it is essential to see if preventive 
measures can reduce the occurrence across cancer types in an ambulatory setting while 
maintaining cost effectiveness (Slade, 2017; Farrington, Cullen, & Dawson, 2013).   
Intervention 
This project began as an effort to help prevent OM in patients, due to the high risk for 
infections, distress, and sepsis in these patients.  Discussions with the oncologist, oncology 
navigators, and oncology certified nurses revealed that current preventive efforts were 
inadequate at the infusion center and that there were no evidenced-based solutions in place. 
The investigation revealed that oral care was taught on a provider preference level and varied 
widely in content and scientific backing.  The initial practice question was, “What can be done to 
prevent OM?”   
As described in chapter 2, the literature provided evidence that an oral care protocol 
needed to be in place as a standard of care.  Also, health care professionals need education on 
OM as well as to be able to teach the OM protocol to patients. Finally, the literature also 
provided evidence that zinc sulfate may prevent or reduce the effects of OM.   
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The primary intervention for this project is zinc sulfate supplementation. Under the 
supervision of a collaborating provider, zinc sulfate supplementation was prescribed to all 
patients receiving oncological therapies under their care. Participants who were supervised 
under the care of other providers within the office served as the control group.  For patients 
wishing to purchase zinc sulfate over the counter, a list of appropriate national brands was 
provided along with the stores that carried them.  Zinc sulfate was dosed at 30 mg, three times 
a day, by mouth based on dosing recommended in a randomized controlled trial in a similar 
patient population (Moslemi et al., 2014).  Participants started zinc sulfate treatment on the day 
of initiation of their chemotherapy after consent for participation was signed.  All participates 
were educated on the oral care protocol, to maintain the standard of care.  Although nausea and 
vomiting can occur with high doses of zinc sulfate, Moslemi and colleagues (2014) found that 
these side effects were not present at the dose used in the RCT.  
The primary intervention was implemented after the facility adopted a standardized oral 
care protocol for all patients receiving oncological treatment. While many staff members at the 
infusion center chose to discuss oral care with their patients receiving oncological therapies, this 
practice was not yet considered standard care at the time of the project. Therefore, an 
evidence-based oral care protocol was developed (See Appendix B-C) and implemented as 
“Phase 1” of this EBP project. Foundation for the oral care protocol that was agreeable to the 
infusion center was developed based on current evidence.   
Staff education about this protocol was delivered by a poster presentation in the staff 
break room, a lunch-and-learn session and example trifold handouts. Educational topics 
included: appropriate use of oral rinses, toothbrush types, suitable toothpaste for use, and 
timing of oral care. A knowledge quiz about the oral care protocol was used to determine if staff 
were adequately prepared to handle the oral care protocol in practice and assist with any 
question patients may present. Nursing knowledge was collected in a pre-and-posttest format 
the following week to ensure readiness and address any areas of weakness before initiation. 
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Staff knowledge about oral mucositis prevention was measured using a 10-item multiple-choice 
quiz developed by the project leader. The questionnaire focused on key points from the oral 
care protocol. Staff completed the questionnaire at baseline and after completing the oral care 
protocol education. Data concerning the pretest and posttest with the team were anonymously 
collected.  One double-sided sheet was used, and names did not appear on the sheets. The full-
time clinical staff manager assisted with distribution and collection of these quizzes. 
Performance on the questionnaires was measured using percentage correct out of the total 
number of quiz items. An average score of 90% indicated that the staff was ready to implement 
the protocol.   
Trifold handouts and education were provided to all patients receiving chemotherapy. 
Trifolds were easy to read, offered visual cues, and offered follow up information about 
symptoms of OM.  Dietary recommendations were added per request of clinical site. Additional 
trifolds were placed in visible areas for ease of access. 
Planning  
This project used the collection of survey data and employed anonymized data for 
patient tracking.  The project received an expedited review process by the Valparaiso University 
Institutional Review Board (IRB), and informed consent was obtained from individual 
participants that met eligibility requirements.  Written permission was obtained from both the 
facility and IRB.    
Data measures 
Reduction of oral mucositis complications was the primary outcome of this EBP project. 
Oral mucositis was measured using item one of the PROMS survey, which measures pain 
severity on a 100-mm visual analog scale. The PROMS has demonstrated high internal 
consistency (Cronbach’s alpha 0.86 – 0.98) and convergent validity (Spearman’s rho -0.43) with 
the Functional Assessment of Cancer Therapy (FACT-G) and the transplantation specific 
subscale (BMT). Divergent validity (Spearman’s rho 0.72) for both ulceration and erythema at 
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seven-day post-treatment was analyzed by correlating the PROMS scale and the Affect Balance 
Scale (ABS) (Kushner et al., 2008).  Also, Kushner et al., (2008) noted a correlation between 
the PROMS tool and the Center for Epidemiologic Studies Depression (CES-D) scale noting 
that on day seven (Spearman's rho 0.51) and day fourteen (Spearman's rho 0.39) there was 
statistical significant direct correlation between OM severity and depression severity. 
Participants in this evidence-based project were assessed using the PROMS at baseline 
(time of treatment initiation) then weekly for an additional five weeks.  
Data collection 
Data concerning OM severity were anonymously collected using the PROMS survey. 
This survey was given to patient participants by the clinical infusion nurse who initiated their 
chemotherapy.  The PROMS was printed on three single-sided sheets that capture 
measurements along a 100-millimeter visual analog scale. It took about 5 to 7 minutes for the 
patient to complete the survey.  When the patient finished the PROMS survey, the tech who 
monitored the infusion areas would write down the number of the chemo bay, the letter of the 
seat the patient was in, and the year of birth.  This number had no connection to the patient 
medical ID, nor did use of this combination of identifiers provide any meaningful information that 
could indicate a patient’s private information. The assignment to chemo bays was not consistent 
which passively helped randomize data.  In the charting system used at the facility, this 
information was easy to see and did not require additional burden of location. The date would 
also be placed on the paper for demographic information review.  At the end of the clinic day, all 
completed PROMS surveys collected and placed in a locked filing cabinet in the clinical 
manager’s office until data could be electronically entered. 
Management and analysis  
Data obtained from PROMS surveys was double entered into an Excel spreadsheet and 
stored on a password-protected USB drive to ensure the accuracy and security of the 
quantitative data.  When a discrepancy occurred, the data was corrected for accuracy.  When 
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the USB drive was not in use, it was stored in a locked filing cabinet that was under constant 
video surveillance monitoring for entrance and exit out of the nurse manager office.  Original 
surveys where then destroyed using the facility provided secure shred service.    
Descriptive statistics were used to describe the sample population.  Data collected 
included age, sex, race, and type of cancer. The mean age and its standard deviation will be 
calculated, and age will be compared between treatment and control groups using independent 
sample t-test. Categorical variables (sex, race, ethnicity, cancer type) will be described using 
frequencies and percentages, and differences in these variables will be compared between 
groups using the chi-square.   
Inferential statistics were used to examine the differences in PROMS scores between 
the two groups using independent sample t-tests. Between-group comparisons occurred at 
baseline (week zero) and at week six. Within-group comparisons occurred at baseline (week 
zero), between week one and week two, between week two and week three, between week 
three and week four, between week four and week five, and between week five and week six.  
All comparisons of PROMS scores were made using the independent samples t-test.   
Protection of Human Subjects 
 Insurance of the protection of human rights occurred throughout the project. The project 
leader was required to undergo training in human rights protection and obtained a certificate of 
completion (NIH, 2018).  All physicians within the practice were committed to complete the 
project, along with consideration to methods already in place.  Additionally, Valparaiso 
University granted IRB approval before initiation of the project.  The treatment center did not 
have a formal IRB process in place. Specific steps to maintain patient confidentiality and 
anonymity were previously described.   
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CHAPTER 4 
FINDINGS 
Oral mucositis is considered one of the most severe non-hematological complications 
that can occur in patients undergoing oncological treatments (Campos et. al, 2014). 
Development of OM can compromise quality of life and result in life-threating bloodstream 
infections (Collen et al., 2018; Eilers et al., 2014).  This condition can affect anywhere from 40 to 
100% of patients receiving various oncological treatments (Eilers et al., 2014; Harada et al., 
2016).  Currently there is no universally accepted protocol for the prevention of OM, though 
efforts to minimize its impact have been completed. This chapter describes the results of a 
quasi-experimental evidence-based practice project, which consisted of a standardized oral 
care protocol for all participants and a prescription for zinc sulfate (300 milligrams by mouth 
once daily) in half of the convenience sample of patients undergoing oncological treatment for 
cancer. The following chapter reviews demographic information and comparisons between the 
intervention (i.e., “zinc”) and control (i.e., “non-zinc”) groups.   
Participants 
Size.  There was a total of 88 possible participants that met inclusion criteria to 
participate in this project.  Of the eligible participants, 23 (26.1%) completed more than one 
survey over the 6-week period, resulting in a final sample size of 23 participants.   
Characteristics. Most respondents were male (n = 14, 60.9%). Almost half of the 
participants were between the ages of 61 and 70 (n = 12, 52.1%), and the remaining 47.9% 
were either between the ages of 41 and 60 (n = 6, 26%) or 71 to 90 (n = 5, 21.7%). The most 
frequently occurring ethnic group was African-American (n = 12, 52.2%).  Whites comprised 
39.1% of the study (n=9).  The remaining 47.8% of the sample were either White (n = 9, 39.1%), 
Asian (n = 1, 4.3%), or Hispanic/Latino (n = 1, 4.3%).  
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Most of the participants in the EBP project were receiving chemotherapies for lung 
cancers (n = 11, 47.8%), breast cancer (n = 3, 13.3%), or colorectal cancer (n = 3, 13.3%).  Two 
participants were being treated for pancreatic cancer (8.7%), and one each (4.3%) for non-
Hodgkin’s lymphoma, leukemia, and laryngeal cancer. Metastases of these cancers were 
common, with 13 participants (56.5%) having cancers beyond the primary site.   
Characteristics of the Treatment Groups. For this project, two groups were compared 
over the 6 weeks(See Figures 4.1 and 4.2).  One group received the standard of care alone, 
and the other group received the standard of care plus a prescription for zinc supplementation. 
In the zinc supplementation group, there was a total of 12 participants (52.2%); in the non-zinc 
supplementation group, there were 11 participants (47.9%).   
Chi-square statistics were used to compare the participants in the zinc group to the 
participants in the non-zinc group.  At baseline, significantly more males were noted in the non-
zinc group than in the zinc supplement group (n = 5 vs. 9, respectively, p = .049). No other 
significant differences were found in any patient characteristics between the zinc and non-zinc 
groups. See table 4.1. 
Changes in Outcomes 
 The EBP project was divided into two phases. The first phase focused on 
implementation of a standardized oral care protocol and staff education. Knowledge was 
assessed before and after implementing the staff education using a 10-item oral care 
knowledge questionnaire. Registered nurses and medical assistants completed the same staff 
education and knowledge questionnaires. The mean pretest score was 64%, and the average 
posttest score was 90%, indicating an increase in staff knowledge about oral care for patients 
receiving oncological treatment.   
The second phase of the project focused on differences in oral health symptoms (mouth 
pain, difficulty speaking, restricted speech, difficulty eating hard foods, difficulty eating soft  
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Table 4.1 Demographics of participants  
Demographic Zinc  
n (%) 
No zinc  
n (%) 
X2 df p-value 
Number of participants 
 
12 11    
Gender      
     Male 5 (41.7) 9 (81.8) 3.884 1 0.049 
     Female 
 
7 (58.3) 2 (18.2)    
Age Range      
     41-50 1 (8.3) 0 5.977 7 0.542 
     51-55 0 2 (18.2)    
     56-60 2 (16.7) 1 (9.1)    
     61-65 3 (25.0) 4 (26.4)    
     66-70 3 (25.0) 2 (18.2)    
     71-75 0 0    
     76-80 2 (16.7) 1 (9.1)    
     81-85 0 1 (9.1)    
     86-90 
 
1 (8.3) 0    
Race      
     Asian 0 1 (9.1) 2.072 3 0.558 
     African-American 6 (50.0) 6 (54.5)    
     Hispanic  1 (8.3) 0    
     White 
 
5 (41.7) 4 (36.4)    
Cancer Types      
     Lung cancer 6 (50.0) 5 (45.5) 6.727 7 0.458 
     Breast cancer 2 (16.7) 1 (9.1)    
     Colorectal cancer 1 (8.3) 2 (18.2)    
     Non-Hodgkin’s lymphoma 1 (8.3) 0    
     Leukemia 1 (8.3) 0    
     Pancreatic cancer 0 2 (18.2)    
     Other endocrine cancer 1 (8.3) 0    
     Laryngeal cancer 
 
0 1 (9.1)    
Metastases      
     No Metastases 7 (58.3) 3 (27.3) 2.253 1 0.133 
     Metastases 5 (41.7) 8 (72.7)    
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foods, restricted eating, difficulty drinking, restricted drinking, difficulty swallowing, and change 
in taste), measured weekly using a 100-millimeter visual analog scale for each symptom, 
between participants in the zinc and non-zinc groups over a 6-week period. Effectiveness of the 
intervention was evaluated by comparing the survey scores of the two groups as they reported 
on the survey.  Data from the visual analog scale were entered and analyzed using SPSS 
version 25 (IBM, 2017). 
Statistical Testing.  
Independent t-tests were used to answer the PICOT question: In patients receiving 
oncological treatments, does an oral care protocol with zinc sulfate supplementation, compared 
to the standard of care (oral protocol alone), reduce complications related to oral mucositis as 
measured by a patient-reported assessment tool over a six-week period? A separate 
independent samples t-test was performed to compare mean scores of the zinc group and the 
non-zinc group each within each week (i.e., within-week between-group comparisons). 
Statistical significance was determined using a level of significance equal to .05.  
Statistically significant differences were found in 8 out of 10 oral mucositis symptoms. 
These differences were more apparent towards the middle and the end of the six-week period, 
with the zinc supplementation group showing fewer symptoms than the control group. The 
symptoms with statistically significant improvement were mouth pain at weeks 5 and 6, difficulty 
speaking at weeks 4 and 6, difficulty eating soft foods at weeks 3 and 5, restriction of eating at 
week 6, difficulty drinking at week 5 and 6, restriction of drinking at week 3, difficulty swallowing 
and week 4 and 5, and change in taste at weeks 4 and 5.. Mean scores and test statistics are 
presented in Table 4.2 and displayed graphically in Figures 4.3 through 4.11. The only 
symptoms without any statistically significant differences were restricted speaking and difficulty 
eating hard foods.  
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Table 4.2 
Differences in Oral Health Symptoms Between Groups 
 Zinc Group 
(n = 12) 
Non-Zinc Group 
(n = 11) 
 
Symptom M SD M SD T p 
Mouth Pain       
Baseline 1.58 1.676 4.36 8.629 -1.05 .124 
Week 2 18.45 25.629 22.5 31.206 -.325 .252 
Week 3 19.40 27.694 16.30 25.016 .263 .637 
Week 4 15.30 19.961 17.22 27.399 -.173 .402 
Week 5 2.91 3.113 8.75 17.169 -.951 .046 
Week 6 2.00 1.549 8.91 15.751 -1.44 .004 
Difficulty Speaking       
Baseline 0.92 1.564 2.27 2.832 -1.40 .394 
Week 2 4.27 5.551 5.60 10.606 -.354 .191 
Week 3 3.10 4.280 4.70 11.026 -.428 .212 
Week 4 2.70 3.401 7.33 11.347 -1.17 .008 
Week 5 2.09 2.023 5.00 7.819 -1.02 .086 
Week 6 1.18 1.471 3.36 6.329 -1.11 .037 
Restricted Speaking       
Baseline 1.33 1.723 2.64 3.585 -1.09 .451 
Week 2 2.64 4.249 6.20 8.509 -1.19 .170 
Week 3 3.50 6.621 5.20 9.508 -.464 .602 
Week 4 3.20 3.048 5.22 6.037 -.906 .372 
Week 5 2.45 2.841 3.38 4.069 -.550 .549 
Week 6 2.00 3.464 3.09 4.763 -.614 .720 
Difficulty Hard Foods       
Baseline 1.67 1.614 6.91 12.454 -1.38 .003 
Week 2 14.09 13.620 18.40 24.158 -.497 .277 
Week 3 11.70 9.499 18.80 22.125 -.932 .214 
Week 4 12.60 9.891 14.67 15.851 -.337 .429 
Week 5 7.91 5.338 15.13 17.932 -1.10 .138 
Week 6 4.82 4.490 10.18 14.442 -1.17 .066 
Difficulty Soft Foods       
Baseline 1.17 1.586 2.64 3.776 -1.19 .163 
Week 2 3.73 5.985 3.70 2.497 .014 .241 
Week 3 2.00 1.414 4.20 4.984 -1.34 .024 
Week 4 3.00 4.422 3.44 2.651 -.269 .453 
Week 5 1.82 1.471 7.25 10.011 -1.52 .008 
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Week 6 2.18 1.779 3.82 4.644 -1.09 .151 
Restricted Eating       
Baseline 1.25 1.765 4.27 6.958 -1.40 .024 
Week 2 11.73 16.304 20.70 23.338 -1.01 .066 
Week 3 7.90 13.585 15.60 21.214 -.967 .338 
Week 4 8.90 10.640 18.89 24.096 -1.14 .073 
Week 5 6.55 12.910 12.00 15.866 -.799 .429 
Week 6 3.45 3.475 11.82 15.112 -1.78 .017 
Difficulty Drinking       
Baseline 1.08 1.621 4.73 8.615 1.38 0.31 
Week 2 2.45 3.588 5.40 5.835 -1.37 .097 
Week 3 2.00 1.700 5.20 8.121 -1.22 .051 
Week 4 2.10 1.912 3.67 3.240 -1.26 .095 
Week 5 2.00 2.324 5.00 6.676 -1.21 .024 
Week 6 1.36 1.859 3.73 5.101 -1.44 .023 
Restricted Drinking       
Baseline 1.00 1.706 1.55 1.753 -.755 .827 
Week 2 2.09 2.548 3.30 2.869 -1.01 .668 
Week 3 1.20 1.033 2.70 3.234 -1.39 .033 
Week 4 1.90 1.853 2.11 2.472 -.209 .430 
Week 5 1.45 1.440 3.25 3.732 -1.29 .050 
Week 6 0.91 1.044 2.55 2.162 -2.26 .251 
Difficulty Swallowing       
Baseline 1.25 1.960 4.73 12.076 -.944 .093 
Week 2 6.55 12.144 8.20 16.936 -.255 .642 
Week 3 3.50 4.035 8.60 20.244 -.781 .103 
Week 4 2.00 1.700 6.89 13.430 -1.08 .048 
Week 5 1.91 1.375 8.25 17.409 -1.02 .027 
Week 6 2.18 1.940 5.27 9.371 -1.07 .148 
Change in Taste       
Baseline 1.17 1.801 5.73 15.730 -.956 .068 
Week 2 8.18 12.360 20.70 25.708 -1.40 .053 
Week 3 7.50 12.430 15.20 25.724 -.852 .215 
Week 4 6.30 8.486 14.33 21.442 -1.05 .045 
Week 5 4.55 7.090 16.88 28.723 -1.18 .040 
Week 6 3.36 4.478 10.91 21.328 -1.14 .052 
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Figure 4.1 Overall Zinc Supplement Group Means
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Figure 4.2 Overall Comparison Group Means
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Figure 4.3 Mouth Pain 
 
Figure 4.4 Difficulty Speaking  
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Figure 4.5 Difficulty Eating Soft Foods
 
Figure 4.6 Restrictions of Eating 
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Figure 4.7 Difficulty Drinking  
 
Figure 4.8 Restrictions of Drinking 
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Figure 4.9 Difficulty Swallowing  
 
Figure 4.10 Change in Taste 
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CHAPTER 5 
DISCUSSION 
Oral mucositis (OM) is an adverse effect that is associated with several distressing 
symptoms in individuals receiving chemotherapy. This condition is a complex inflammatory 
process that can progress to ulcerative lesions, decrease the quality of life due to pain and 
eating restrictions, and promote the development of life-threatening infections (Collen et al., 
2018; Eilers et al., 2014).  OM is the most common cause of non-hematological complications 
and increases morbidity in individuals undergoing treatment (Campos et. al, 2014).   
The purpose of this EBP project was to explore if zinc supplementation in addition to an 
oral care protocol reduced the complications of OM when compared to the oral care protocol 
alone. Participants filled out a subjective survey, the PROMS, weekly for six weeks. Data for 
both groups were recorded then tested for statistical significance. Statistical significance was 
found in 8 out of 10 symptoms that were tracked on the PROMS survey.  The statistical 
significance was most prominent starting towards the middle of the six weeks and continued to 
the end of the six weeks data was collected.   
 Explanation of Findings.  Results from the statistical analyses were provided in 
Chapter 4. Overall, the group that was treated with zinc sulfate had less severe symptoms at 
various time points during the six-week period, although these differences were not statistically 
significant for all symptoms or at all times. Instead, differences in symptom severity did not 
appear to be statistically significant until Week 4 for most symptoms. This is consistent with the 
existing literature on zinc supplementation, which found that patients receiving oncological 
treatment for head and neck cancers who were treated with zinc sulfate supplementation had a 
shorter duration and reduced OM symptoms (Moslemi et al., 2014).  
 No statistically significant differences were noted in the groups in relation to restriction of 
speech or difficulty eating hard foods when completing the independent t-test. This could be in 
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part due to the small sample size, which, given the presumably small effect size of zinc sulfate 
on oral mucositis symptoms, may not have provided adequate statistical power to avoid a type II 
error. However, shorter duration of symptoms may be linked to use of zinc, which is why finding 
a statically significant in week six is noteworthy (Eilers et al., 2014).     
 Significant findings between groups may have been diminished due to participants 
having freedom to choose their own zinc supplementation. Zinc is not a prescription medication 
and is common at many local retailers. Participants were not provided a preference list for 
brands since there are many price points and brands to choose from. Participants purchased 
brands based on their individualized preference. The use of multiple zinc supplement brands 
that were purchased from both retail and online market places could have varied in quality, 
purity, and even type of zinc used.  Since there was little control over the independent 
purchases, and random error may have had a considerable effect on these analyses.   
 Zinc comes in many different formations, with the best-absorbed oral types of zinc 
including zinc citrate, zinc acetate, or zinc picolinate (Turner, 2013).  However, best available 
evidence focused on use of zinc sulfate in studies (Moslemi et al., 2014 & Yarom et al., 2013).  
The literature supporting this EBP project failed to specify why zinc sulfate was chosen over 
formulations, so it is possible that the use of zinc sulfate rather than better-absorbed zinc salts 
could have contributed to a reduced treatment effect in this project. 
Most of the participants were male for this EBP project (n = 14, 61%), but there were 
disproportionately more males in the control group (n = 9) than in the zinc group (n = 5), 
resulting in a statistically significant result (p=0.05). This was the only statistically significant 
difference at baseline in terms of patient characteristics, and it is unclear if this had any effect on 
the OM outcomes. Elder and colleagues (2013) found that men have less health confidence, 
which hinders their ability to fully engage in self-care at home. Since this EBP project required 
diligent self-care and a rigorous schedule of oral hygiene to complete several times throughout 
the day, it is possible that the high number of male participants in the non-zinc group (and thus 
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relied solely on following the self-driven oral hygiene protocol) were less comfortable managing 
self-care. More sophisticated analyses that looks at a mixed effect between sex and treatment 
group on OM symptoms may be useful in making this determination. 
The types of cancers that this EBP project encountered differed greatly. The goal was to 
determine if zinc sulfate was a viable option across all cancer types, and it appears that there 
may be some benefit to using zinc sulfate for treatment of OM, regardless of the underlying type 
of cancer. However, it is not possible from this small sample to conduct more sophisticated 
analyses that would look for differences in outcomes between cancer types. Furthermore, the 
risk of developing OM varies based on cancer type and treatment modality, with some cancers 
having the risk of development for OM estimated at a minimum of 20% while cancer of the head 
and neck developing at a rate of almost 100% (Cullen et al., 2018; McGuire et al., 2013; 
Panachi et al., 2016 &Yarom et al., 2013). A larger sample size would make it possible to 
control for these variables, at least to differentiate “head and neck cancers” from “non-head and 
neck cancers”. Unfortunately, this was not possible in this project.  
 Cancer advancement or metastases may have contributed to the variation in mean OM 
severity between the two groups. The non-zinc group had a higher rate of participants with 
cancers that metastasized from their original location (n = 8, 72%) compared to the zinc group 
(n = 5, 41%). The type of oncological treatments or primary cancer site in the group with 
metastasis, and therefore the overall risk for developing OM at all, may have varied from those 
that did not present with metastasis. This may account for the mean symptom severity in the 
non-zinc group being consistently higher across all areas.   
Evaluation of Applicability of Theoretical and EBP Frameworks 
Theoretical Framework: Dorothea Orem’s Self-Care Nursing Theory.  Dorothea 
Orem’s Self-Care Nursing Theory was used as the theoretical framework for this project. Orem’s 
theory involves three interrelated concepts: self-care, self-care demands, and self-care agency 
(Griffin & Landers, 2014). Self-care addresses the concept that individuals preform certain tasks 
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throughout their lives in the interest of maintaining their health, function, development, and well-
being by meeting self-care requisites (Orem,2001). Self-care is the desire of one’s willingness to 
preform care on their own behalf. Self-care demands, according to Orem’s theory, include the 
degree and kinds of care that an individual may need at a specific point in time or across a 
duration of time (Remeo et al., 2018). Self-care requisites are the demands can be thought of as 
activities of daily care that help control or manage an individual’s self-care. Self-care agency in 
Orem’s theory addresses an individual’s ability to complete tasks of self-care (Orem, 2001).  
There are several factors that contribute to self-agency: age, developmental state, health state, 
sociocultural orientation, and environmental factors (Fawcett & DeSanto-Madeya, 2013).   
Since this project relied on all participants following an oral care protocol and the zinc 
supplement group requiring purchasing and taking zinc, this theory was appropriate. The  
primary investigator spent time educating participants on the oral care protocol. Part of the 
eligibility criteria for participating in this project was that the participant would have appropriate 
self-care agency by being able to functionally and cognitively preform oral care. Educational 
handouts were given to patients as reference, as a manner to help reinforce the educational 
points for the oral care protocol.   
One reason why Orem’s Self-Care Nursing Theory is appropriate is because it 
addresses situational illnesses, which occur for a specified period of time. Since cancer 
treatment is usually situational, the theory is appropriate to guide this self-care-based 
intervention.  
EBP Framework: Johns Hopkins Nursing Evidenced-Based Practice Model 
(JHNEBP Model).  The JHNEBP Model is an open system with three interrelated concepts: 
inquiry, practice, and learning. The open system allows and accommodates for both internal and 
external factors to be incorporated into the model (Dang & Dearholt, 2017). For this EBP project 
internal factors included organizational culture, beliefs, supplies, and staffing. The organizational 
culture for the EBP project was one that fostered learning.  The physicians would often have 
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small meetings about changes that were occurring, both in office, but also new treatments and 
studies that were going on.  They were receptive to questions and explained the rationales 
behind their support of the intervention or why the evidence did not convince them that zinc 
supplementation would change the course of OM. An open culture of information exchange 
among all staff helped the JHNEBP Model follow the required steps and plan as needed to fit 
the needs of their office.  
External factors included external stakeholders, insurance companies and external 
influences on purchasing.  Stake-holders included the patients who came there for 
chemotherapy treatments, the people that they brought for support, as well as the larger 
communities that they dwelled in.  The JHNEBP Model helped the staff to be consistent in 
addressing oral care and zinc supplementation once the project was implemented, thus 
affecting all involved in the patient care.  Due to the socioeconomical factors within the 
population the intervention as intentionally kept low cost.  Insurance companies could also be 
considered stakeholders because the overarching goal was to prevent or reduce the 
complications of OM.  It is possible that if sustainability is achieved, it could save on hospital 
admission cost.   
Inquiry was the first step for this EBP project. It encouraged addressing a problem and 
discovering solutions in novel and innovative ways. For this EBP project, the question examined 
if there was a way to prevent or reduce the impact of OM in patients receiving outpatient 
chemotherapy treatments. The JHNEBP Model encouraged looking past old methods and 
becoming innovative based on the evidence. After the literature was evaluated, the interventions 
synthesized from the data strongly supported use of an oral care protocol and zinc 
supplementation, both of which were low cost, patient driven interventions. Patient involvement 
in their own care as well as their symptoms reported subjectively, help contain cost because it 
did not require more assessment or documentation on the providers and their staff who worked 
in the busy office, thus also working towards cost containment.   
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The next step is practice, which is the transition phase of putting what is already known 
into the task that is going to be done, while it addresses nursing standards and helps ensure 
that nurses operate within their scope of practice. Since the primary investigator was 
experienced in acute oncology care expectations for time in the facility had to be discussed. 
Due to the close association between the acute care and clinical outpatient site, the primary 
investigator was well known within the office.  Three of the employees, including the nurse 
manager of the clinical site, had formally worked with the primary investigator.  The expectations 
had to be outlined, so the outpatient clinical staff understood that I could not go above my role 
as a DNP student, and that I would not be able to assist with starting IVs, managing 
chemotherapy infusions, or other roles which I was not orientated to do within that office.   
Part of the practice step was ensuring that the clinical staff was onboard with the 
intervention. Initially, when the project was presented, many of the employees expressed that 
oral care was not important and that they provided adequate oral care education.  However, 
once the pretest score was provided the staff acknowledged that they needed more education 
and they became more receptive to the intervention.  When they were educated on zinc sulfate, 
which is an over the counter supplement, the nurses did not feel comfortable discussing this 
with patients voicing concerns that the patients could overdose.  They were educated on the 
amount needed, based on results from previous studies, and it was noted to be well within safe 
limits.  Ultimately, the physician who overseen the intervention group provided them with an 
educational print out and the reassurance that they could safely take it while receiving 
chemotherapy. The participants were more receptive to hearing it from the overseeing physician 
than the primary investigator and office staff.   
The next phase is the learning phase. The JHNEBP Model learning is considered an 
ongoing process and allows to change when there is new information, clinical practices or other 
factors that can improve current processes. This model for EBP practice establishes that 
learning is life long and project teams should be interprofessional and collaborative in nature 
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(Dang & Dearholt, 2017). The team for this EBP project consisted of multidisciplinary personal, 
all working towards the same goal.   
 For example, the development of the oral care protocol was an ongoing process 
between the primary investor and the physicians within the practice.  The original version 
included only oral care information, however, they physicians felt it could be improved by adding 
dietary recommendations, suggested toothpaste brands, and more specific lip care instructions.  
Through various editing, this information was added, along with the recipe for making the mouth 
rinses for patients who could not afford saline solutions.  Another example of change that took 
place during the learning phase was who would issue the surveys to the participants.  Originally, 
it was proposed that the front desk provide the PROMS survey to patients at check-in, however, 
they did not know who participants were and were not able to distinguish if an appointment was 
for chemotherapy or another type of treatment.  Working with office flow, the process changed 
to have the medical assistants give and collect the surveys to participants in the absence of the 
primary investor.  By inclusion of all the roles in the office, it allowed the development of a more 
organic and easier to follow chain of events that ensured the standard of care and the 
intervention was being addressed.   
The JHNEBP Model systematically addresses questions through the practice question 
that is being explored, the evidence concerning the practice, and then the transition into 
practice. This process is referred to by the acronym PET. Since the model is open, new EBP 
processes can be triggered throughout this cycle (Dang & Dearholt, 2017). For this EBP project, 
the transition phase from Evidence Synthesis into the Practice took the longest due to 
requested changes in the oral care protocol and educational materials after the project had 
already been approved. Educational trifolds originally addressed only the oral care protocol, 
however, the multidisciplinary team requested dietary information be included as well. The later 
version also included recommended brands of toothpaste and two recipes for oral rinse solution. 
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A final revision was requested that included recommendations for lip care. The final education 
trifold for patients is presented in Figure 5.1. 
There were several characteristics of the JHNEBP Model that made it a good fit for this 
project. First, it was flexible enough to withstand a variety of both internal and external factors 
that could have derailed the project. Second, the model prompted the investigator to solicit 
feedback and partnership from a multidisciplinary team at the implementation site. This turned 
out to be an essential key to the success of this project. Third, the JHNEBP Model also provides 
comprehensive tools for novices to follow, giving step by step guides that move towards project 
implementation including identification of stakeholders, steps of the PET process, evidence 
assessment and appraisal tools, action planning, and dissemination tools. In summary, the 
Model proved to be user-friendly, team-focused, and promoted deeper thinking about what 
would and would not work at the implementation site.  
While the JHNEBP Model is highly utilized, it is not without limitations.  Facilities that are 
not familiar with EBP must be taught some of the core principles and be provided with more 
information about sequences of steps.  For example, developing a list of who could serve as 
change champions in their respected areas was a step that needed to be taken.  Instead of 
accepting the idea that everyone would immediately adopt the interventions, it was important to 
have someone within their area to be able to reinforce the importance of the interventions.  This 
allowed for two-way valuable feedback to the primary investigator about what was working well 
and about what processes needed to change.  A notable time when feedback was helpful was 
when there was discussion of the clinic providing the zinc supplementation.  After analysis, this 
plan was decided not to be incorporated because of fears of medications storage, counting, and 
meeting accreditation standards.  Strengths and Limitations of the EBP Project 
Strengths. There were several strengths attributed to this project. One strength was the 
implementation site, which proved to be large enough for participant recruitment, but small 
enough that workflows and processes were relatively straightforward. Moreover, the 
ORAL MUCOSITIS PREVENTION  82 
  
 
organizational culture was one that fully supported evidence-based practice and embraced the 
self-care theoretical underpinnings of this intervention. Upon formal approval of the EBP project 
from the physician owner of the implementation site, the clinical providers, nurses, medical 
assistants, and human resources staff provided whatever support was necessary to implement 
and evaluate this project. For example, one physician within the site encouraged staff to attend 
the education sessions held prior to implementing the project. The nursing manager also held 
the staff accountable for completing knowledge questionnaires and collecting specific data (e.g. 
types of therapy) if the investigator was unavailable. 
The second strength was the use of a validated measurement tool for oral mucositis 
symptom severity. The PROMS scale was easy for participants to understand and it used a 
100-millimeter visual analog scale; both of these features served to minimize measurement 
error in this small sample, which allowed for the highest possible power during statistical 
analysis. Furthermore, the prepared survey could be completed at the participants chosen pace 
during their oncological treatment session, and it required no additional work for clinic staff.   
The third strength of this project’s findings was the high proportion of African-American 
participants, which comprised more than half of the sample. Current research has not been 
generalizable to clinics in areas with a large African-American population. However, this project 
has done so. 
Limitations. This project had some important limitations. The original proposal included 
the distribution of oral care kits to participants, which included a soft-bristled toothbrush, a 
recommended tooth paste, and packets to make saline for oral rinses. However, the process of 
obtaining these items would have significantly delayed implementation due to the purchasing 
process of the facility, so this intervention was dropped due to it not being feasible. 
There had also been consideration of providing the participants with zinc sulfate 
supplementation capsules and methods of replenishing them weekly basis. Concerns arose that 
there would need to be pill counts, additional materials to both identify and transport the pills 
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once out of labeled bottle and tracking system for who should receive the pills weekly. Nursing 
staff voiced concerns that this would create undue burden to their task flow and the office 
manager worried about meeting all the standards by regulatory bodies. This measure was also 
dropped due to the cumbersome process that would have needed to be established to meet 
various needs and requirements.   
Perhaps the most important limitation was the small sample size.  There was a total of 
88 people who met the inclusion criteria for the project, yet only 23 filled out the informed 
consent and completed more than one survey. Throughout the recruitment process, it was 
noted that potential participants would often decline to enroll because they were tired or anxious 
during their first chemotherapy treatments. Therefore, a recruitment approaches that addresses 
these limitations is recommended in the future.   
Convenience sampling may have also had an impact on results.  Participants were 
grouped by provider managing their care in the office.  However, this resulted in the comparison 
group having a higher number of participants with more advanced cancers due to metastasis, 
which made it unclear whether the worse symptom severity in this group was due to the 
absence of zinc supplementation, or to the advanced nature of the cancer.  
  Implications for the Future 
Practice. Review of evidence indicated that zinc supplementation in addition to an oral 
care protocol may be more effective than and oral care protocol alone. The outcomes of this 
EBP project did show consistent statistically significant results in 8 out 10 areas assessed by 
the PROMS survey, especially towards the middle and end weeks. This is consistent with 
findings in the literature.  This does not support that data that zinc sulfate may prevent OM 
symptoms, however, it could suggest that it reduces the duration of symptoms. More 
sophisticated investigation is needed to determine if zinc supplementation is appropriate to 
provide to all patients receiving chemotherapy. It is recommended to assess zinc sulfate as an 
OM prevention initiative in a more controlled setting, with a larger sample size, over a longer 
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duration, and with a more consistent distribution of participant sample groups to ensure that 
similar cancer types and cancer stages are equally represented. Based on the results from this 
project, zinc sulfate with an oral care protocol seems to help reduce the intensity and duration of 
OM systems when surveyed using the PROMS questionnaire, but results are not generalizable, 
therefor zinc should not be prescribed until further investigation is completed.  
Theory. Dorothea Orem’s Self-Care Nursing Theory was beneficial in that it helped 
develop information that focused on self-care. It allowed the primary investigator to interact with 
participants in a dynamic context, and it helped them develop the tools to engage in the self-
care at home in efforts to prevent OM. The JHNEBP Model was helpful for the novice primary 
investigator. It provided tools, such as a stakeholder analysis that included the intended purpose 
of the tool, definitions and how to use the tool.  The action planning tool was also helpful to a 
novice for project implementation. It served as a guide to ensure successful transitions of 
interventions into practice.  The action plan tool, helped the novice primary investigator consider 
things such as barriers, how the change would affect the health record, workflow, or policies.  It 
also referenced support and cost.  The final page included documentation of milestones and 
related task. These tools are immensely helpful when working towards implementation of an 
evidence-based project.   
Research.  While exploring if zinc sulfate help prevent or reduce the incidents of OM 
was the foundation for this EBP project, the effectiveness of establishing an oral care protocol 
as a preventive measure was not explored due to it becoming the standard of care.  The oral 
care protocol was the strongest supported finding in the evidence, however, the construct of the 
EBP project did not allow the exploration of if this step alone was enough to produce significant 
results.  Future research should incorporate appropriate time to do pre-implementation 
measures of OM, thus making this project three phases instead of the two explored by this EBP 
project.  There may also be benefits to investigating overall dietary textures and providing 
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education about restrictions to soft foods only since questions addressing soft foods had much 
lower mean scores in both groups and maybe of some benefit.   
 The two phased project implementations at the facility caused a significant delay in the 
initiation of the second phase which was where participant data was collected.  Phase one 
consisted of development of the oral care protocol and the education of staff which were two of 
the major themes from the best available evidence.  The largest delay, however, came from the 
development of oral care protocol trifold handouts which participants received as an educational 
reference.  The trifold was developed by the primary investigator and then modified to meet the 
needs of the facility, however, this process took away from valuable time in which participants 
could have been recruited into the study.   
 More research could be applied to the dietary portion of oral care.  Refining what 
constituted “soft food” or “hard food” seemed to be a patient specific experience.  For example, 
toast was considered a soft food to some participants, and a hard food for others.  One 
participant noted they considered hard foods items difficult to chew, such as meat but noted 
breaded chicken as a soft food. Using the oral care protocol from another facility may prevent 
delays such as this when future research is conducted.  
 Outcomes could have been affected by the demographics for the patients.  For example, 
most of the participants were male.  Another interesting characteristic this project captured was 
a high number of African American participants.  Lung cancer was the most common kind of 
cancer to be treated in this project, which could have also affected the results.  More 
sophisticated investigation is needed to see if these characteristics contributed to the results.  
Ideally, upon repeat investigation, these characteristics should be considered as an area of 
importance.   
Education. Because OM can have such devastating effects on those that receive 
oncological treatments, prevention or reduction of OM symptoms should be incorporated as an 
important part holistic care. All outpatient facilities should establish an oral care protocol as a 
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cost effective, patient driven intervention to prevent OM.  Oral care protocols should be taught to 
patients by staff, patients should receive easy to read instructions, and OM symptoms should be 
tracked through the duration of treatment by a subjective patient tool.  More sophisticated 
investigation is needed to determine if zinc sulfate supplementation if viable to reducing OM.  
The small sample size, demographic characteristics, and convenience sampling does not allow 
this study to be generalizable to all patients receiving chemotherapy treatments.    
Education of the clinical professional is also valuable.  While many may know different 
parts of oral care, no standard oral care protocol exists. Clinicians in all fields may encounter 
persons who receive oncological type treatments and it is important to provide them with 
methods based in science to help reduce complications.   
Conclusion 
 Oncological treatments result in cytotoxic effects that can lead to the development of 
OM.  Oral mucositis is one of the most severe non-hematological problems related to 
chemotherapies.  This condition can result in poorer quality of life, weight loss, pain, and 
increased risk for hospitalization and death related to sepsis.  Review of evidence lead to four 
major themes which were incorporated into this EBP project: Use of an oral care protocol, use 
of patient reported OM tools, professional clinical knowledge OM, and zinc sulfate may be 
effective as a preventive supplement. This project found that zinc sulfate 300 milligrams by 
mouth once daily, plus a standardized oral care protocol, was more effective at reducing OM 
symptom severity than the standardized oral care protocol alone. The use of a standardized oral 
care protocol would be beneficial to any outpatient area that administers chemotherapy, 
however more research is needed to determine if zinc sulfate supplementation can be given to 
all patients receiving chemotherapy. 
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Appendix A: PROMS survey  
 
 
This questionnaire asks you to evaluate some situations you may have experienced 
in the past week.  
 
All of the situations refer to the condition of your mouth. You can indicate the 
severity of the situation by placing a vertical mark along the lines below. 
 
First, we will use this type of line to rate temperature as an example. 
On a hot day in the middle of the summer, if we asked you to rate how warm it was 
today, you would probably mark the line as follows: 
 
not warm 
at all  
 
 
 
extremely 
warm 
 
On a cool day in fall, you might indicate:  
 
not warm 
at all  
 
 
 
extremely 
warm 
 
On a cold day in winter, you might indicate:   
 
not warm 
at all  
 
 
 
extremely 
warm 
 
 
To practice: Please tell me how warm it is outside today by placing a mark on the 
line below:   
 
not warm 
at all  
 
 
 
extremely 
warm 
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Appendix A: PROMS survey (continued) 
 
Now that you know how to use this scale, please indicate to what degree these 
situations have affected you in the past week. 
Mouth pain 
 
 
no pain  
 
 
 
worst 
possible 
pain 
 
Difficulty speaking because of mouth sores 
 
no 
trouble 
speaking  
 
 
 
impossible 
to speak 
 
Restriction of speech because of mouth sores 
 
no 
restriction 
of speech  
 
 
 
complete 
restriction 
of speech 
 
Difficulty eating hard foods (hard bread, potato chips, etc.) because of mouth 
sores 
 
no trouble 
eating 
hard foods  
 
 
 
impossible 
to eat hard 
foods 
 
Difficulty eating soft foods (jello, pudding, ect.) because of mouth sores 
 
no 
trouble 
eating 
soft 
foods  
 
 
 
impossible 
to eat soft 
foods 
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Appendix A: PROMS survey (Continued) 
 
Restriction of eating because of mouth sores 
 
no 
restriction 
of eating  
 
 
complete 
restriction 
of eating 
 
Difficulty drinking because of mouth sores 
 
no 
trouble 
drinking  
 
 
 
impossible 
to drink 
 
Restriction of drinking because of mouth sores 
 
no 
trouble 
drinking  
 
 
 
complete 
restriction 
of 
drinking 
 
Difficulty swallowing because of mouth sores 
 
not 
difficult 
to 
swallow   
 
 
 
impossible 
to 
swallow 
 
Change in taste 
 
no 
change in 
taste  
 
 
 
complete 
change 
in taste 
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Appendix B: Oral care protocol trifold (front) 
 
 
ORAL MUCOSITIS PREVENTION  97   
 
Appendix C: Oral care protocol trifold (back)  
 
